



Coronavirus: An invisible lethal terror

Kalyan Kumar De ¹

Molecular Biology Laboratory, Hooghly Mohsin College, Hooghly, Chinsurah, W.B., India

Abstract: There is a new public health crises threatening the world with the emergence and spread of 2019 novel coronavirus (2019-nCoV) or the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus originated in bats and was transmitted to humans through yet unknown intermediary animals in Wuhan, capital city of Hubei province and a major transportation hub of China in December 2019. There have been around 22, 92, 93,200 reported cases of coronavirus disease 2019 (COVID-2019) and 47, 05,498 reported deaths to date (20/09/2021). The disease is transmitted by inhalation or contact with infected droplets and the incubation period ranges from 2 to 14 days. The symptoms are usually fever, cough, sore throat, breathlessness, fatigue, malaise among others. The disease is mild in most people; in some (usually the elderly and those with comorbidities), it may progress to pneumonia, acute respiratory distress syndrome (ARDS) and multi organ dysfunction. Many people are asymptomatic. Fortunately so far, children have been infrequently affected with no deaths. But the future course of this virus is unknown. Diagnosis is by demonstration of the virus in respiratory secretions by special molecular tests. Treatment is essentially supportive; role of antiviral agents is yet to be established. Prevention entails home isolation of suspected cases and those with mild illnesses and the treatment of patients with severe infection and symptoms is specially done at hospital that includes the treatment in ICU with strict control measures as per protocol guided by WHO. Few safe and effective vaccines discovered recently will prevent the illness after vaccination and save millions of lives. Beside this, wearing a mask, repeatedly washing hands and maintenance of social distance are the most important precautionary measures against COVID-19. The global impact of this new epidemic is yet uncertain.

Keywords: Coronavirus, 2019-nCoV, COVID-19

1. Introduction and Etymology

Coronaviruses are a group of retro- or RNA viruses that cause diseases in mammals. In humans, they cause respiratory tract infection that can range from mild to lethal. Mild illnesses in humans include some cases of the common cold (which is also caused by other viruses, predominantly rhinoviruses), while more lethal varieties can cause SARS (Sever Acute Respiratory Sndrome), MERS (Middle-East Respiratory Sndrome) and COVID-19 Corona Virus Disease -2019).

Viruses are actually ultramicroscopic, acellular, obligate parasite; they exhibit two distinct phases in their activity, such as extracellular phase and intracellular phase – in former phase viruses behave like non-living i.e. inanimate objects while in latter phase they behave like living organisms within the host-cells. Viruses contain single or double stranded either DNA or RNA, (as genetic material) but never both.

In December 2019, adults in Wuhan, capital city of Hubei province and a major transportation hub of China started to suffer from severe pneumonia of unknown cause and admitted to local hospitals. Many of the initial cases had a common exposure to the Huanan wholesale seafood market that also traded live animals.

The respiratory samples of patients were sent to reference laboratory for etiologic investigations. On December 31st 2019, China notified the outbreak to the World Health Organization and on 1st January the Huanan sea food market was closed. On 7 January the virus was identified as a novel coronavirus (2019-nCoV) that had >95% homology with the bat coronavirus and > 70% similarity with the SARS-CoV signifying that the virus originated from there [1]. This virus spreads faster than

¹ Email: kalyannet2003@yahoo.co.in

its two ancestors the SARS and MERS. The number of cases of coronavirus disease started increasing exponentially due to the fact of human-to-human transmission. The first fatal case was reported on 11th January 2020. The massive migration of Chinese during the Chinese New Year fuelled the epidemic. Cases in other provinces of China, other countries (Thailand, Japan and South Korea in quick succession) were reported in people who were returning from Wuhan. Transmission to healthcare workers caring for patients was described on 20th January, 2020. Cases of COVID-19 in countries outside China were reported in those with no history of travel to China suggesting that local human-to-human transmission was occurring in these countries [2]. Airports in different countries including India put in screening mechanisms to detect symptomatic people returning from China and placed them in isolation and testing them for COVID-19. Soon it was apparent that the infection could be transmitted from asymptomatic people and also before onset of symptoms. Therefore, countries including India who evacuated their citizens from Wuhan through special flights or had travellers returning from China placed all people symptomatic or otherwise in isolation for 14 days and tested them for the virus.

By 5th March, 2020, 29 cases had been reported; mostly in Delhi, Jaipur and Agra in Italian tourists and their contacts. One case was reported in an Indian who travelled back from Vienna and exposed a large number of school children in a birthday party at a city hotel. Many of the contacts of these cases have been quarantined.

These numbers are possibly an underestimate of the infected and dead due to limitations of surveillance and testing. Though the SARS-CoV-2 originated from bats, the intermediary animal through which it crossed over to humans is still unknown.

The name "coronavirus" is derived from Latin *corona*, meaning "crown" or "wreath" (Fig. 1). The name was coined by June Almeida and David Tyrrel who first observed and studied human coronaviruses [3]. The name refers to the characteristic appearance of virion (single infective form or particle of the virus) by electron microscopy, which has a fringe of large, bulbous surface projections creating an image of the *solar corona* or *halo* [1, 3]. This morphology is created by the viral protein spike.

This article gives a bird's eye view about this new virus. Since knowledge about this virus is rapidly evolving, readers are urged to update themselves regularly.




Fig. 1: (A) *Coronavirus*, (B) *Crown with spike* and (C) *Solar corona/halo during eclipse*

2. Origin of Human Coronavirus

Many human coronaviruses have their origin in bats (Fig. 2) [4]. The human coronavirus shared a common ancestor with a bat coronavirus [5]. MERS-CoV emerged in humans from bats through the intermediate host of camels [6]. MERS-CoV, although related to several bat coronavirus species, appears to have diverged from these several centuries ago [7]. The ancestors of SARS-CoV first infected leaf-nose bats; subsequently, they spread to horseshoe bats, then to Asian palm civets, and finally to humans [8, 9]. The intermediary animal through which it crossed over to humans from bats is uncertain. Pangolins and snakes are the current suspects.




Fig. 2: *Origins of human coronaviruses with possible intermediate hosts*

3. Ultrastructure of Coronavirus

Coronaviruses are large, roughly spherical particles with unique spike-like surface projections [10]. Their size is highly variable with average diameters of 80 to 120nm. Extreme sizes are known from 50 to 200 nm in diameter [11]. The total molecular mass is on average 40,000kDa.

They are enclosed in an envelope embedded with a number of protein molecules [12]. The lipid bilayer envelope, membrane proteins, and nucleocapsid protect the virus when it is outside the host cell [13]. The viral envelope is made up of a lipid bilayer in which the membrane (M), envelope (E) and spike (S) structural proteins are anchored [14]. The molar ratio of E: S: M in the lipid bilayer is approximately 1:20:300 [15]. The E and M protein are the structural proteins that combined with the lipid bilayer to shape the viral envelope and maintain its size [16]. S proteins are needed for interaction with the host cells. The diameter of the envelope is 85 nm. The envelope of the virus in electron micrographs (Fig. 3) appears as a distinct pair of electron-dense shells (shells that are relatively opaque to the electron beam used to scan the virus particle) [17, 16].

The M protein is the main structural protein of the envelope that provides the overall shape and is a type III membrane protein. It consists of 218 to 263 amino acid residues and forms a layer 7.8 nm thick [11]. It has three domains, a short N-terminal ectodomain, a triple-spanning transmembrane domain, and a C-terminal endodomain. The C-terminal domain forms a matrix-like lattice that adds to the extra-thickness of the envelope. The M protein is crucial during the assembly, budding, envelope formation, and pathogenesis stages of the virus lifecycle [18].

The E proteins are minor structural proteins and highly variable in different species [10]. There are only about 20 copies of the E protein molecule in a coronavirus particle [14]. They are 8.4 to 12 kDa in size and are composed of 76 to 109 amino acids [10]. They are integral proteins (i.e. embedded in the lipid layer) and have two domains namely a transmembrane domain and an extramembrane C-terminal domain. They are almost fully α -helical, with a single α -helical transmembrane domain, and form pentameric (five-molecular) ion channels in the lipid bilayer (Fig. 4). They are responsible for virion assembly, intracellular trafficking and morphogenesis (budding) [11].




Fig. 3: *Transmission electron micrograph of coronaviruses*




Fig. 4: (A) Illustration of a coronavirus, (B) Diagrammatic view of the structure of coronavirus

The spikes are the most distinguishing feature of coronaviruses and are responsible for the corona- or halo-like surface. On average a coronavirus particle has 74 surface spikes [19]. Each spike is about 20 nm long and is composed of a trimer of the S protein. The S protein is in turn composed of an S₁ and S₂ subunit. The homotrimeric S protein is a class I fusion protein which mediates the receptor binding and membrane fusion between the virus and host cell (Fig. 5). The S₁ subunit forms the head of the spike and has the receptor-binding domain (RBD). The S₂ subunit forms the stem which anchors the spike in the viral envelope and on protease activation enables fusion. The two subunits remain noncovalently linked as they are exposed on the viral surface until they attach to the host cell membrane [11]. In a functionally active state, three S₁ are attached to two S₂ subunits. The subunit complex is split into individual subunits when the virus binds and fuses with the host cell under the action of proteases such as cathepsin family and transmembrane protease serine 2 (TMPRSS2) of the host cell [20].




Fig.5 After binding of the ACE2 receptor, coronavirus spike is activated and cleaved at the S1/S2 level

S1 proteins are the most critical components in terms of infection. They are also the most variable components as they are responsible for host cell specificity. They possess two major domains named N-terminal domain (S1-NTD) and C-terminal domain (S1-CTD), both of which serve as the receptor-binding domains. The NTDs recognize and bind sugars on the surface of the host cell. S1-CTDs are responsible for recognizing different protein receptors such as angiotensin-converting enzyme 2 (ACE2), aminopeptidase N (APN), and dipeptidyl peptidase 4 (DPP4) [11].

Inside the envelope, there is the nucleocapsid, which is formed from multiple copies of the nucleocapsid (N) protein, which are bound to the positive-sense single-stranded RNA genome in a continuous beads-on-a-string type conformation (Fig. 6) [16, 21]. N protein is a phosphoprotein of 43 to 50 kDa in size, and is divided into three conserved domains. The majority of the protein is made up of domains 1 and 2, which are typically rich in arginines and lysines. Domain 3 has a short carboxy terminal end and has a net negative charge due to excess of acidic over basic amino acid residues [10].

Coronavirus contains a positive-sense, single-stranded RNA genome. Positive-strand RNA viruses (+ssRNA viruses) are a group of related viruses that have positive-sense, single-stranded genomes made of ribonucleic acid. The positive-sense genome can act as messenger RNA (mRNA) and can be directly translated into viral proteins by the host cell's ribosomes. Positive-strand RNA viruses encode an RNA-dependent RNA polymerase (RdRp) which is used during replication of the genome to synthesize a negative-sense anti-genome that is then used as a template to create a new positive-sense viral genome.

The genome size for coronavirus is 30 kilobases [22]. The genome has a 5' methylated cap and a 3' polyadenylated tail [16].

The genome organization for a coronavirus is 5'-leader-UTR-replicase (ORF1ab)-spike (S)-envelope (E)-membrane (M)-nucleocapsid (N)-3'UTR-poly (A) tail. The open reading frames 1a and 1b, which occupy the first two-thirds of the genome, encode the replicase polyprotein (pp1ab). The replicase polyprotein self cleaves to form 16 non-structural proteins (nsp1–nsp16) [16].

The later reading frames encode the four major structural proteins: spike, envelope, membrane, and nucleocapsid [23]. Interspersed between these reading frames are the reading frames for the accessory proteins. The number of accessory proteins and their function is unique depending on the specific coronavirus [16].

4. Entry of Coronavirus causing infection in Human body

All ages are susceptible. Infection is transmitted through watery droplets (diameter = 0.5-12 μ) generated during coughing and sneezing (contains 40,000 droplets per sneezing) by symptomatic patients but also occurs from asymptomatic people and before onset of symptoms [24]. Studies have shown higher viral loads in the nasal cavity as compared to the throat with no difference in viral burden between symptomatic and asymptomatic people [25]. Patients can be infectious for as long as the symptoms last and even on clinical recovery. The virus can remain viable on surfaces for days in favourable atmospheric conditions but are destroyed in less than a minute by common disinfectants like sodium hypochlorite, hydrogen peroxide etc. [26]. Infection is acquired either by inhalation of these droplets through nose or touching surfaces contaminated by them or then touching the nose, mouth and eyes. The virus is also present in the stool and contamination of the water supply and subsequent transmission via aerosolization/feco oral route is also hypothesized [27]. As per current information, transplacental transmission from pregnant women to their fetus has not been described [28]. However, neonatal disease due to post natal transmission is described [28]. The incubation period varies from 2 to 14 days.

Human coronaviruses mainly infect the epithelial cells of the respiratory tract and also a wide range of cells and systems of the body, while animal coronaviruses generally infect the epithelial cells of the digestive tract [29].

Coronavirus infects the human epithelial cells of the lungs via an aerosol route [30]. Studies have identified angiotensin receptor 2 (ACE₂) as the receptor through which the virus enters the respiratory mucosa [31]. Coronavirus is most known for affecting the upper respiratory tract (sinuses, nose, and throat) and the lower respiratory tract (windpipe and lungs) [32]. The lungs are the organs most affected by coronavirus because the virus accesses host cells via the receptor for the enzyme angiotensin-converting enzyme 2 (ACE2), which is most abundant on the surface of type II alveolar cells of the lungs [33]. Infection begins when the viral spike glycoprotein attaches to its complementary host cell receptor. After attachment, a protease of the host cell cleaves and activates the receptor-attached spike protein and allows the virus to enter the host cell by endocytosis or direct fusion of the viral envelope with the host membrane [34].

On entry into the host cell, the virus particle is uncoated, and its genome enters the cell cytoplasm. Finally it hijacks the entire cellular machinery of the host cell. The coronavirus RNA genome has a 5' methylated cap and a 3' polyadenylated tail, which allows it to act like a messenger RNA and be directly translated by the host cell's ribosome. The host ribosomes translate the initial overlapping open reading frames ORF1a and ORF1b of the virus genome into two large overlapping polyproteins, pp1a and pp1ab [35].




Fig. 6: Diagrammatic view of the structure of coronavirus and its genome structure in details

The larger polyprotein pp1-ab is a result of a -1 ribosomal frameshift caused by a slippery sequence (UUUAAAC) and a downstream RNA pseudo-knot at the end of open reading frame ORF1a [36]. The ribosomal frameshift allows for the continuous translation of ORF1a followed by ORF1b [35].

The polyproteins have their own proteases, PLpro(nsp3) and 3CLpro (nsp5), which cleave the polyproteins at different specific sites. The cleavage of polyprotein pp1ab yields 16 nonstructural proteins (nsp1 to nsp16). Product proteins include various replication proteins such as RNA-dependent RNA polymerase (nsp12), helicase (nsp13), and exoribonuclease (nsp14) [35].

A number of the nonstructural proteins coalesce to form a multi-protein replicase-transcriptase complex. The main replicase-transcriptase protein is the RNA-dependent RNA polymerase (RdRp). It is directly involved in the replication and transcription of RNA from an RNA

strand. The other nonstructural proteins in the complex assist in the replication and transcription process.

One of the main functions of the complex is to replicate the viral genome. RdRp directly mediates the synthesis of negative-sense genomic RNA from the positive-sense genomic RNA. This is followed by the replication of positive-sense genomic RNA from the negative-sense genomic RNA [35].

The replicated positive-sense genomic RNA becomes the genome of the progeny viruses. The mRNAs are gene transcripts of the last third of the virus genome after the initial overlapping reading frame. These mRNAs are translated by the host's ribosomes into the structural proteins and many accessory proteins [35]. RNA translation occurs inside the endoplasmic reticulum. The viral structural proteins S, E, and M move along the secretory pathway into the Golgi intermediate compartment. There, the M proteins direct most protein-protein interactions required for the assembly of viruses following its binding to the nucleocapsid. Progeny viruses are then released from the host cell by exocytosis through secretory vesicles. Once released, the viruses can infect other healthy host cells [37]. The virus may also enter the bloodstream from the lungs and is able to spread and invade to also a wide range of cells and systems of the body through blood. In severe COVID-19 cases, lung cells are damaged and the lung shows the patches of lesions (Fig. 7) in the lung.




Fig. 7: A CT scan of a patient with COVID-19 shows lesions (bright regions) in the lungs

Most people who get COVID-19 have mild or moderate symptoms like coughing, a fever, and shortness of breath. But some who catch the new coronavirus get severe pneumonia (Fig. 8) in both lungs. COVID-19 pneumonia is a serious illness that can be deadly. Pneumonia is a lung infection that causes inflammation in the tiny air sacs inside your lungs. They may fill up with so much fluid and pus that it's hard to breathe and the patient may have severe shortness of breath, a cough, a fever, chest pain, chills, or fatigue.



Fig. 8: Chest X-ray showing COVID-19 pneumonia




Fig. 9: *Transmission and life-cycle of coronavirus causing COVID-19*




Fig. 10: Pathogenesis of coronavirus: (1) coronavirus enters the epithelial cell and gets released after completing their life cycle; (2) infection induces inflammatory factors; (3) Antigen presentation of coronavirus and (4) in severe COVID-19 cases, the virus reaches the lower respiratory tract

Coronavirus infection induces inflammatory factors that lead to activation of macrophages and dendritic cells (Fig. 9). Antigen presentation of coronavirus via major histocompatibility complexes I and II (MHC I and II) stimulates humoral and cellular immunity resulting in cytokine and antibody production. . In severe COVID-19 cases, the virus reaches the lower respiratory tract and infects type II pneumocytes leading to apoptosis and loss of surfactant. The influx of macrophages and neutrophils induces a cytokine storm. A cytokine storm can be a complication in the later stages of severe COVID-19. A cytokine storm is a potentially deadly immune reaction where a large amount of pro-inflammatory cytokines and chemokines are released too quickly; a cytokine storm can lead to ARDS and multiple organ failure [38]. China indicates that patients who had more severe responses to

COVID-19 had greater amounts of pro-inflammatory cytokines and chemokines in their system than patients who had milder responses; these high levels of pro-inflammatory cytokines and chemokines indicate presence of a cytokine storm [39]. Leaky capillaries lead to alveolar edema. Hyaline membrane is formed. All of these pathological changes result in alveolar damage and collapse, impairing gas exchange.

The immune response (Fig. 10) by humans to coronavirus occurs as a combination of the cell-mediated immunity and antibody production [40], just as with most other infections [41]. B cells interact with T cells and begin dividing before selection into the plasma cell, partly on the basis of their affinity for antigen [42]. The presence of neutralizing antibodies in blood strongly correlates with protection from infection, but the level of neutralizing antibody declines with time. Those with asymptomatic or mild disease had undetectable levels of neutralizing antibody two months after infection. In another study, the level of neutralizing antibodies fell four-fold one to four months after the onset of symptoms. However, the lack of antibodies in the blood does not mean antibodies will not be rapidly produced upon re-exposure to coronavirus. Memory B cells specific for the spike and nucleocapsid proteins of corona last for at least six months after the appearance of symptoms [43].

Whether coronavirus is able to invade the nervous system remains unknown. However, it is clear that many people with COVID-19 exhibit neurological or mental health issues. The virus is not detected in the CNS (Central Nervous System) of the majority of COVID-19 people with neurological issues. However, coronavirus has been detected at low levels in the brains of those who have died from COVID-19, but these results need to be confirmed [44]. Loss of smell results from infection of the support cells of the olfactory epithelium, with subsequent damage to the olfactory neurons [45]. coronavirus could cause respiratory failure through affecting the brain stem as other coronaviruses have been found to invade the CNS. While virus has been detected in cerebrospinal fluid of autopsies, the exact mechanism by which it invades the CNS remains unclear and may first involve invasion of peripheral nerves given the low levels of ACE2 in the brain [46, 47, 48]. The virus may also enter the bloodstream from the lungs and cross the blood-brain barrier to gain access to the CNS, possibly within an infected white blood cell [44].

The coronavirus also affects gastrointestinal organs as ACE2 is abundantly expressed in the glandular cells of gastric, duodenal and rectal epithelium [49] as well as endothelial cells and enterocytes of the small intestine [50].

The coronavirus can cause acute myocardial injury and chronic damage to the cardiovascular system [51]. Rates of cardiovascular symptoms are high, owing to the systemic inflammatory response and immune system disorders during disease progression, but acute myocardial injuries may also be related to ACE2 receptors in the heart. [51] ACE2 receptors are highly expressed in the heart and are involved in heart function [51, 52]. A high incidence of thrombosis and venous thromboembolism have been found in people transferred to Intensive care units (ICU) with COVID-19 infections. Blood vessel dysfunction and clot formation are thought to play a significant role in mortality, incidences of clots leading to pulmonary embolisms, and ischemic events within the brain have been noted as complications leading to death in people infected with SARS-CoV-2. Infection appears to set off a chain of vasoconstrictive responses within the body, constriction of blood vessels within the pulmonary circulation has also been posited as a mechanism in which oxygenation decreases alongside the presentation of viral pneumonia [53]. Furthermore, micro vascular (arterioles and capillaries) blood vessel damage has been reported in a small number of tissue samples of the brains – without detected SARS-CoV-2 – and the olfactory bulbs from those who have died from COVID-19 [54, 55, 56]. COVID-19 was also found to cause substantial – including morphological and mechanical – changes to blood cells – such as increased sizes – sometimes persisting for months after hospital discharge [57, 58].

Another common cause of death is complications related to the kidneys [59]. Early reports show that up to 30% of hospitalized patients both in China and in New York have experienced some injury to their kidneys, including some persons with no previous kidney problems [60].

Biological factors (immune response) and the general behaviour (habits) can strongly determine the consequences of COVID-19 [61]. Most of those who die of COVID-19, have pre-existing (underlying) conditions, including hypertension, diabetes mellitus, and cardiovascular disease [62]. The most common comorbidities are hypertension (66% of deaths), type 2 diabetes (29.8% of

deaths), Ischemic Heart Disease (27.6% of deaths), atrial fibrillation (23.1% of deaths) and chronic renal failure (20.2% of deaths).

Most critical respiratory comorbidities are: moderate or severe asthma, pre-existing COPD (Chronic Obstructive Pulmonary Disease), pulmonary fibrosis, cystic fibrosis [63]. Smoking can be associated with worse outcomes [64, 65].

5. Symptoms of COVID-19

COVID-19 affects different people in different ways. Most infected people will develop symptoms of COVID-19 which are variable, ranging from mild symptoms to severe illness.

(i) Most common symptoms:

Fever
Cough
Tiredness
Loss of taste or smell

(ii) Less common symptoms:

Sore throat
Headache
Aches and pains
Diarrhoea
A rash on skin, or discolouration of fingers or toes
Red or irritated eyes

(iii) Serious symptoms:

Difficulty breathing or shortness of breath
Loss of speech or mobility, or confusion
Chest pain
Acute respiratory distress syndrome (ARDS)

People with mild symptoms who are otherwise healthy should manage their symptoms at home.

On average it takes 5–6 days from when someone is infected with the virus for symptoms to show, however it can take up to 14 days. Of people who show symptoms, 81% develop only mild to moderate symptoms (up to mild pneumonia), while 14% develop severe symptoms (dyspnea, hypoxia, or more than 50% lung involvement on imaging) and 5% of patients suffer critical symptoms (respiratory failure, shock, or multiorgan dysfunction) [66]. At least a third of the people who are infected with the virus do not develop noticeable symptoms at any point in time [67, 68]. These asymptomatic carriers tend not to get tested and can spread the disease [68, 69, 70, 71]. Other infected people will develop symptoms later, called "pre-symptomatic", or have very mild symptoms and can also spread the virus [71].

Most of those who die of COVID-19 have pre-existing (underlying) conditions or the most common comorbidities like hypertension (66% of deaths), type 2 diabetes (29.8% of deaths), Ischemic Heart Disease (27.6% of deaths), atrial fibrillation (23.1% of deaths) and chronic renal failure (20.2% of deaths) moderate or severe asthma, pre-existing COPD ((Chronic Obstructive Pulmonary Disease), pulmonary fibrosis, cystic fibrosis. When someone with existing respiratory problems is infected with COVID-19, they might be at greater risk for severe symptoms [72]. Several research papers also suggest that smoking can be associated with worse outcomes [73, 74]. CDC (The Centers for Disease Control and Prevention) issued a caution that tuberculosis (TB) infections could increase the risk of severe illness or death with COVID-19. COVID-19 also poses a greater risk to

people who opioids and methamphetamines, insofar as their drug use may have caused lung damage [75].

Pregnant women who do get infected with coronavirus are more likely to have a severe illness than women who aren't pregnant. There's not enough research yet to know if coronavirus can spread to babies during pregnancy or birth. The virus has not been found in amniotic fluid or breast milk, but some babies born to mothers with coronavirus have tested positive for the virus. Newborns can catch the virus from an infected parent. The CDC says it's unlikely that the virus can pass from a mother with confirmed COVID-19 to her unborn baby (a process known as vertical transmission). Research on COVID-19 is still ongoing, but one small study published in December 2020 supports this: Researchers looked at women who tested positive for the coronavirus in their third trimester and found no signs of the virus in maternal or cord blood or in the placenta, and no evidence of viral transmission to the newborn. Some experts suggest that children might not be as severely affected by COVID-19 because there are other viruses that spread in the community and cause diseases such as the common cold. Since children often get colds, their immune systems might be primed to provide them with some protection against COVID-19. It's also possible that children's immune systems interact with the virus differently than do adults' immune systems.

Angiotensin converting enzyme 2 (ACE2) is the main receptor for the entry of SARS-CoV-2 into human cells. This receptor is present on many cells including epithelial cells of the nasopharynx, lungs, heart, kidney, intestine, liver, testis, placenta, central nervous system and blood vessels, as well as macrophages. Furthermore, it has also been postulated that children have ACE2 receptors with a lower affinity for SARS-CoV-2 and a different distribution across body sites, making the entry of SARS-CoV-2 into cells more difficult.

In addition to the ACE2 receptor, SARS-CoV-2 entry into cells involves transmembrane serine protease 2 (TMPRSS2), which cleaves the viral spike protein. TMPRSS2 is absent among children and has been reported to increase with age on nasal and lung epithelial cells. So, babies and children remain protected and react negatively to COVID-19.

There is a common question among layman why are some people infected with COVID-19 asymptomatic? Researchers worldwide have been surprised to see that individuals can be infected with the virus that produces COVID-19 - without showing symptoms. Since these individuals expose others to infection without knowing it, it is important to find an explanation.

On the inside of our lungs are specialized immune cells, called alveolar macrophages, which help maintain a healthy environment in the lungs. The lungs contain a large number of alveolar macrophages, so they are probably also the first cell type an invading virus encounters. When the body recognizes a viral infection, our immune system initiates the production of interferons. Interferons are a group of cytokines that help shape the immune response and are therefore essential in the fight against viral infection. Alveolar macrophages have previously been shown to produce large amounts of interferons upon infection with respiratory viruses. Coronavirus is a respiratory virus that typically infects the outermost cell layer of the lungs, the epithelial layer. New research has shown that interferon production in the infected epithelial cells can be inhibited by the SARS-CoV-2 virus. This result is the low interferon production and therefore also a limited activation of the immune system to fight against the virus. Although the epithelial layer is the target of the virus, it must be assumed that the first cell type the virus encounters is the alveolar macrophages, and therefore these cells are important for how quickly an immune response to a SARS-CoV-2 infection can be initiated. Those people, whose alveolar macrophages response is very fast, become asymptomatic.

6. COVID-19 testing

The WHO has published several testing protocols for COVID-19. Besides the suspected cases, the COVID-19 test should do on all people for screening the actual number of infected cases in a place or country. There are several methods for detecting corona infected person. But the most reliable, effective and specific diagnosis is by specific molecular tests known as reverse transcription.




Fig.11: Flow diagram of RT-PCR technique for diagnosis of COVID-19



Fig.12: Collection of swabs from nasopharyngeal or throat regions for diagnosis of COVID-19

polymerase chain reaction (RT-PCR) (Fig. 11). This test is done from the respiratory samples obtained by a nasopharyngeal swab (Fig. 12). However, throat swab, sputum, endotracheal aspirates and bronchoalveolar lavage sample may also be used [76, 77]. Sensitivity of clinical samples by RT-PCR is 63% for nasal swab, 32% for pharyngeal swab, 48% for faeces, 72–75% for sputum, and 93–95% for bronchoalveolar lavage [78].

Reverse transcription or real time (the actual time during which a process takes place or an event occurs) polymerase chain reaction (RT-PCR) first uses reverse transcription to obtain DNA, followed by PCR to amplify that a small, well-defined segment of DNA many hundreds of thousands of times, creating enough of it for analysis. Test samples are treated with certain chemicals [79, 80] that allow DNA to be extracted. Reverse transcription converts RNA into DNA. The RT-PCR process generally requires a few hours [81]. These tests are also referred to as molecular or genetic assays [82].

This test detects the presence of viral RNA if present in the sample, but not infectious virus. The sample is treated with several chemical solutions that remove substances such as proteins and fats and that extract only the RNA present in the sample.

The viral RNA is reverse transcribed to viral DNA using a specific enzyme known as reverse transcriptase (RT). It is also known as RNA-dependent DNA polymerase that is a DNA polymerase enzyme that transcribes single-stranded viral RNA into viral DNA.

The viral DNA is then placed in an RT-PCR machine or thermocycler. The machine cycles through temperatures that heat and cools the viral DNA to trigger specific chemical reactions that create new, identical copies of the target sections of viral DNA. The cycle is repeated over and over to continue copying the viral DNA. Each cycle doubles the previous number: two copies become four; four copies become eight, and so on. A standard real time RT-PCR set-up usually goes through 40 cycles, which means that, by the end of the process, around a few billion new copies of the viral DNA are created from each strand of the virus present in the sample. For the amplification or doubling of copies of viral DNA, a specialized heat stable enzyme known as *taq* polymerase and a primer are essentially needed. As new copies of the viral DNA are built, the marker labels attach to the DNA strands and then release a fluorescent dye, which is measured by the machine's computer and presented in real time on the screen. The computer tracks the amount of fluorescence in the sample after each cycle. When a certain level of fluorescence is surpassed, this confirms that the virus is present. The suspected case is then diagnosed and confirmed as corona positive case.

7. Treatment

There is no specific, effective treatment or cure for coronavirus disease 2019 (COVID-19). Treatment is essentially supportive and symptomatic. The first step for a suspected corona patient is to ensure adequate isolation to prevent transmission to other healthy people and family members. Mild illness should be managed at home with thorough counselling about danger signs. The usual principles are maintaining hydration and nutrition and controlling fever and cough. Body's oxygen level of the patient is frequently checked by digital oxymeter. If the oxygen level goes beyond 92, the patient is immediately given oxygen support or the patient is immediately admitted to hospital for non-invasive ventilation. Paracetamol medicine is given to the patients to relieve symptoms like fever, body ache, cough etc. Antibiotics and antifungals medicines are also given to suppress the co-infections. Zinc tablets. Vitamin C tablets and multivitamins are also used as supportive medicines to improve the status of body's immunity. Among some hospitalised patients with COVID-19, a few corticosteroid drugs were applied for clinical trials in a wide range of conditions for its anti-inflammatory and immunosuppressant effects. Recovery was found to have benefits for critically ill patients. However, the role of corticosteroids is unproven; while current international consensus and WHO advocate against their use, Chinese guidelines do recommend short term therapy with low-to-moderate dose corticosteroids in COVID-19 ARDS [83, 84]. Some antiviral drugs such as ribavirin, lopinavir-ritonavir have been used based on the experience with SARS and MERS. Remdesivir, a broad spectrum anti RNA drug developed for Ebola in management of COVID-19 [85] was approved or authorized for emergency use to treat COVID-19 in around 50 countries. Remdesivir acts as a nucleoside analog and inhibits the RNA-dependent RNA polymerase (RdRp) of coronaviruses including SARS-CoV-2. Remdesivir is incorporated by the RdRp into the growing RNA product and allows for addition of three more nucleotides before RNA synthesis stalls. There is, as of now, no approved treatment for COVID-19.

A group of Chinese scientists report the isolation of two human monoclonal antibodies with the potential to treat and to prevent SARS-CoV-2 infections, the causative agent of COVID-19.

Monoclonal antibodies are identical copies of an antibody that targets one specific antigen. Scientists can make monoclonal antibodies experimentally by exposing white blood cells to a particular antigen. They can then select a single white blood cell or clone and use this as the basis to produce many identical cells, making many identical copies of the monoclonal antibody. The two monoclonal antibodies block binding of the spike protein of the virus to the host cell's receptor preventing entry. Such antibodies hold great promise for treatment as they are expected to prevent the virus spreading from cell to cell and have their strong ability to resist the virus. This drug is administered intravenously.

8. Prevention

The well known phrase is “prevention is better than cure”. Since COVID-19 has no effective treatment and definite control measure to reduce the chances of infection, so it is better to take some important preventive measures so that we can keep ourselves safe and avoid the disease. Effective preventive measures against COVID-19 are as follows:

1. Staying at home during pandemic situation and lockdown period or containment areas declared by government.
2. Wearing a face mask, hand gloves and head cap in public.
3. Maintain 2 meters social or physical distance from others, avoid crowded places
4. Use hand sanitizer and wash hands frequently with hand wash or soap and water for at least twenty seconds.
5. Ventilate indoor space
6. Avoid touching the eyes, nose or mouth with unwashed hands.
7. Convalescent plasma therapy and COVID-19 vaccines.

In view of the rising number of Covid-19 cases, Lockdown (closing of market, shops, institution, office and transports) period is generally declared by the government of any country to block the transmission of the virus and by this orders it limits the movement of the entire population of a country for certain period as a preventive measure against the COVID-19 pandemic. According to the Union Ministry for Health and Family Welfare, containment zones are specific geographic areas where Covid-19 positive cases are found in large numbers. Such zones are identified by the government and local transmission is prevented.

The WHO and the US CDC recommend individuals wear non-medical face coverings in public settings where there is an increased risk of transmission and where social distancing measures are difficult to maintain [86,87]. This recommendation is meant to reduce the spread of the disease by asymptomatic and pre-symptomatic individuals and is complementary to established preventive measures such as social distancing [87, 88]. Face coverings limit the volume and travel distance of expiratory droplets dispersed when talking, breathing, and coughing [87,88]. A face covering will also filter out particles containing the virus from inhaled and exhaled air, reducing the chances of infection [89]. Many countries and local jurisdictions encourage or mandate the use of face masks or cloth face coverings by members of the public to limit the spread of the virus [90]. When in any room or vehicle with another person, cover coughs and sneezes with a tissue, regularly wash hands with soap and water and avoid sharing personal household items [91, 92]. , The CDC recommends the use of N95 type of mask. N stands for “Non-Oil” meaning that if no oil-based particulates are present, then you can use the mask in the work environment. Masks ending in a 95 have 95 percent efficiency.

During the COVID-19 pandemic, social distancing measures have been implemented nearly worldwide in order to slow the spread of the disease. Social distancing, or physical distancing,[93,94,95] is a set of non-pharmaceutical interventions or measures taken to prevent the spread of a contagious disease by maintaining a physical distance between people and reducing the number of times people come into close contact with each other[93,96]. It involves keeping a distance of six feet or two meters from others and avoiding gathering together in large groups [97, 98]. During the COVID-19 pandemic, social distancing and related measures were emphasised by several governments as alternatives to an enforced quarantine of heavily affected areas.

Our unwashed hands are a critical vector for transmitting microorganisms. So, hand washing with soap and water for at least 20 s or the use of alcohol-based (60%) hand sanitizers when soap and

water are not available is the first line of defence in stopping the spread of infection. Hand washing should be done before or after: touching eyes, nose or mouth, touching masks, entering and leaving a public place, touching an item or surface that may be frequently touched by other people such as door handles, tables, gas pumps, shopping carts, mobile or keyboard of computer etc.

Ventilation is the process of introducing fresh air into indoor spaces while removing stale air. Letting fresh air into indoor spaces can help remove air that contains virus particles and prevent the spread of coronavirus (COVID-19). Opening windows and doors (when the weather permits) increases the outdoor ventilation rate in a room. Ensuring proper ventilation with outside air can help reduce indoor airborne contaminants, including SARS-CoV-2, the virus that causes COVID-19, and other viruses. To help prevent infections, keep the hands away from eyes, nose, and mouth especially during the COVID-19 pandemic. Why? The mucous membranes of such organs are a portal of entry for germs that cause respiratory infections, including COVID-19.

It is estimated that people touch their face about 23 times per hour! Respiratory infections can be caused by many different bacteria and viruses, including the virus that causes COVID-19. When anybody touches face, the germs on hands can take up residence in the mucous membranes and cause infections, including COVID-19 infections.

Respiratory infections, like pneumonia, flu, or COVID-19, can spread through droplets in the air when a sick person coughs, sneezes, or talks near others. They can also spread by direct contact with bacteria, viruses, and other disease-causing germs. When we touch people who are sick, or touch dirty surfaces, we contaminate our hands with germs. We can then infect ourselves with those germs by touching our face.

Convalescent plasma therapy and COVID-19 vaccines are used as a preventive measure to protect the majority of people from hospitalisation and death from COVID-19. Before the discovery of COVID-19 vaccine, convalescent plasma therapy uses blood from people who've recovered from an illness to help others recover. Transferring purified and concentrated antibodies produced by the immune systems of those who have recovered from COVID-19 to people who need them is being investigated as a non-vaccine method of passive immunisation. Viral neutralization is the anticipated mechanism of action by which passive antibody therapy can mediate defence against SARS-CoV-2.

A COVID-19 vaccine is a vaccine intended to provide acquired immunity against coronavirus that causes coronavirus disease 2019 (COVID-19). The COVID-19 vaccines are widely credited for their role in reducing the spread, severity, and death caused by COVID-19. As of 13 October 2021, 6.56 billion doses of COVID-19 vaccines have been administered worldwide based on official reports from national public health agencies. At the initial stage of COVID-19, there was no vaccine existed for preventing a coronavirus infection in humans. Scientists throughout the world were trying to develop an effective and safe vaccine, but all were in trial. As with all medicines, every vaccine must go through extensive and rigorous testing to ensure it is safe before it can be introduced in a country's vaccine programme.

Each vaccine under development must first undergo screenings and evaluations to determine which antigen should be used to invoke an immune response. This preclinical phase is done without testing on humans. An experimental vaccine is first tested in animals to evaluate its safety and potential to prevent disease. If the vaccine triggers an immune response, it is then tested in human clinical trials in three phases. The entire process takes long time and after that it is sent to government for its approval for large scale production and marketing. A vaccine forces our immune system to make antibodies against a specific disease. Then, if we come into contact with them again, our immune system knows what to do. The vaccine gives us immunity, so we don't get sick or so our illness is much milder than it otherwise would have been.

There are four categories of vaccines in clinical trials: whole virus, protein subunit, viral vector and nucleic acid (RNA and DNA). Some of them try to smuggle the antigen into the body, others use the body's own cells to make the viral antigen. All of them are trying to achieve the same thing – immunity to the virus, and some might also be able to stop transmission. They do so by stimulating an immune response to an antigen, a molecule found on the virus. In the case of COVID-19, the antigen is typically the characteristic spike protein found on the surface of the virus, which it normally uses to help it invade human cells.

Many conventional vaccines use whole viruses to trigger an immune response. There are two main approaches. Live attenuated vaccines use a weakened form of the virus that can still replicate

without causing illness. Inactivated vaccines use viruses whose genetic material has been destroyed so they cannot replicate, but can still trigger an immune response. Both types use well-established technology and pathways for regulatory approval, but live attenuated ones may risk causing disease in people with weak immune systems. Inactivated virus vaccines can be given to people with compromised immune systems. Covaxin (code named as BBV152) is an inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research -National Institute of Virology.

Subunit vaccines (Fig. 13) use pieces of the pathogen - often fragments of protein - to trigger an immune response. This type of COVID-19 vaccine contains harmless S proteins. Once our immune system recognises the S proteins it creates antibodies and defensive white blood cells. Doing so minimises the risk of side effects, but it also means the immune response may be weaker. This is why they often require adjuvants, to help boost the immune response. Adjuvants are substances formulated as part of a vaccine to boost immune responses and enhance a vaccine's effectiveness.




Fig. 13: *Protein subunit vaccine (Courtesy: Mayo Foundation for medical Education and Research)*

Messenger RNA (mRNA) vaccine (Fig. 14) is a type of vaccine that uses genetically engineered mRNA to give our cells instructions for how to make the S protein found on the surface of the COVID-19 virus. After vaccination, your immune cells begin making the S protein pieces and displaying them on cell surfaces. This causes our body to create antibodies. If we later become infected with the COVID-19 virus, these antibodies will fight against the virus. The Pfizer vaccine (BioNTech COVID-19 Vaccine) uses messenger RNA (mRNA). This is what carries the instructions for making the “spike” protein that lets the virus enter human cells. The mRNA vaccine tells our immune cells to make the protein and act as if they’ve already been infected with the coronavirus, giving us some immunity against it.




Fig. 14: mRNA vaccine (Courtesy: Mayo Foundation for medical Education and Research)

Vector vaccine is a type of vaccine, genetic material from the COVID-19 virus is placed in a modified version of a different virus (viral vector). When the viral vector gets into our cells, it delivers genetic material from the COVID-19 virus that gives our cells instructions to make copies of the S protein. Once our cells display the S proteins on their surfaces, our immune system responds by creating antibodies and defensive white blood cells. If we later become infected with the COVID-19 virus, the antibodies will fight the virus.

Viral vector vaccines (Fig. 15) can not cause you to become infected with the COVID-19 virus or the viral vector virus. Also, the genetic material that's delivered doesn't become part of our DNA. The Janssen/Johnson & Johnson COVID-19 vaccine is a vector vaccine. AstraZeneca and the University of Oxford also have a vector COVID-19 vaccine.




Fig. 15: Viral vector vaccine (Courtesy: Mayo Foundation for medical Education and Research)

In India three vaccines were approved for vaccination for example Covaxin, Covisheild and Sputnik V. The CoviShield COVID-19 (AZD1222) (C19VAZ) vaccine, formerly known as ChAdOx1 nCoV-19, is made from a virus (ChAdOx1), a weakened version of a common cold virus

(adenovirus). In addition, genetic material has been added to the ChAdOx1 construct, which is used to make proteins from the SARS-CoV-2 coronavirus called Spike glycoprotein (S). On February 15, 2021, the World Health Organization (WHO) recommended the Serum Institute of India Pvt Ltd COVID-19 Vaccine (ChAdOx1-S [recombinant]) known as COVISHIELD. This vaccine was co-developed by AstraZeneca Plc and the University of Oxford on January 1, 2021.

In May 2020, Indian Council of Medical Research's (ICMR's) National Institute of Virology approved and provided the virus strains for developing a fully indigenous COVID-19 vaccine (Covaxin). In June 2020, the company received permission to conduct Phase I and Phase II human trials of a developmental COVID-19 vaccine. In November 2020, Covaxin received the approval to conduct Phase III human trials after completion of Phase I and II.

The Russian COVID-19 vaccine Sputnik V (Gam-COVID-Vac) is an adenoviral-based, two-part vaccine against the SARS-CoV-2 coronavirus. Initially produced in Russia, Sputnik V uses a weakened virus to deliver small parts of a pathogen and stimulate an immune response.

The Sputnik V (Gam-COVID-Vac) vaccine reduces the time taken for the actual development of immunity to SARS-CoV-2, the betacoronavirus behind the COVID-19 pandemic.

It is a vector vaccine based on adenovirus DNA, in which the SARS-CoV-2 coronavirus gene is integrated. Adenovirus is used as a "container" to deliver the coronavirus gene to cells and start synthesizing the new coronavirus's envelope proteins, "introducing" the immune system to a potential enemy. The cells will use the gene to produce the spike protein. The person's immune system will treat this spike protein as foreign and produce natural defences, antibodies, and T cells, against this protein.

The CDC also says the vaccines are safe for pregnant women and there is no indication they pose any danger to the fetus. There have been reports of adverse allergic reactions to some of the vaccines, so at present time; people who have a history of severe allergies are advised not to get vaccinated.

9. Post-COVID Complicacy

Although most people with COVID-19 get better within weeks of illness, some people experience a range of new or ongoing symptoms that can last weeks or months after first being infected with the virus that causes COVID-19. Unlike some of the other types of post-COVID conditions that tend only to occur in people who have had severe illness, these symptoms can happen to anyone who has had COVID-19, even if the illness was mild, or if they had no initial symptoms. People commonly report experiencing different combinations of the following symptoms:

- Difficulty breathing or shortness of breath
- Tiredness or fatigue
- Symptoms that get worse after physical or mental activities (also known as post-exertional malaise)
- Difficulty thinking or concentrating (sometimes referred to as "brain fog")
- Cough
- Chest or stomach pain
- Headache
- Fast-beating or pounding heart (also known as heart palpitations)
- Joint or muscle pain
- Pins-and-needles feeling
- Diarrhoea
- Sleep problems
- Fever
- Dizziness on standing (light-headedness)
- Rash
- Mood changes
- Change in smell or taste
- Changes in menstrual period cycles

10. Conclusion

The COVID-19 pandemic has affected the world in various ways. This new virus outbreak has challenged the economic, medical and public health infrastructure of the world. Time alone will tell us how we conquer the virus. Although, the severity of the virus has been reduced little bit, still its outburst is continuing. This pandemic needs the cooperation and awareness of entire populations to reduce the spread of the disease. The government should develop effective strategies and give topmost priority to prevent the outbreaks of virus. During COVID-19 pandemic and long term lockdown period, many people have lost their job. In general overall economic condition touched the sediment. So, at the same time, it is also important that government should try to improve the economic condition of the people of their own country.

Acknowledgement

Author is thankful to Dr. Saibal Ray, Associate Professor, Department of Physics. Government College of Engineering and Ceramic Technology for his continuous incitement and for the consideration of publication of my review article in this journal.

References

- [1] Xinhua. China's CDC detects a large number of new coronaviruses in the South China seafood market in Wuhan. Available at: https://www.xinhuanet.com/2020-01/27/c_1125504355.htm.
- [2] R. Camilla, S. Mirjam, S. Peter, B. Gisela, F. Guenter, W. Claudia, Z. Thorbjörn, T. Verena, J.Christian, G. Wolfgang, S. Michael, D. Christian, V. Patrick, Z. Katrin, Z. Sabine, W. Roman and H. Michael, *N. Engl. J. Med.* **382** (2020) 970.
- [3] Q. Li, X. Guan and P. Wu, *N. Engl. J. Med.* **10** (2020) 1056.
- [4] D. Forni, R. Cagliani and M. Sironi, *M. Trends in Microbiology* **25** (2017) 35.
- [5] J. Huynh, S. Li, B. Yount, A. Smith, L. Sturges and J.C. Olsen, *J. Virology* **86** (2012) 12816.
- [6] S.K. Lau, K.S. Li, A.K. Tsang, C.S. Lam, S. Ahmed and H. Chen, *J. Virology* **87** (2013) 8638.
- [7] M.A. Gouilh, S.J. Puechmaile, J.P. Gonzalez, E. Teeling, P. Kittayapong, J.C. Manuguerra, *Infection, Genetics and Evol.* **11** (2011) 1690.
- [8] D. Vijaykrishna, G.J. Smith, J.X. Zhang, J.S. Peiris, H. Chen, Y. Guan, *J Virology* **81** (2007) 4012.
- [9] J. Cui, Han N, Streicker D, G. Li, X. Tang and Z. Shi, *Emerging Infectious Diseases* **13** (2007) 1526.
- [10] C.S. Goldsmith, K.M. Tatti, T.G. Ksiazek, P.E. Rollin, J.A. Comer and W.W. Lee, *Emerging Infectious Diseases* **10** (2004) 320.
- [11] P.S. Masters, *Adv. Virus Research* **66** (2006) 193.
- [12] K. Lachhandama, *Sci. Vision* **20** (2020) 78.
- [13] B.W. Neuman, G. Kiss, A.H. Kunding, D. Bhella, M.F. Baksh and S. Connelly, *J. Structural Biology* **174** (2011) 11.
- [14] M.M. Lai and D. Cavanagh, *Adv. Virus Res.* **48** (1997) 1.

- [15] M. Godet, R. L'Haridon, J.F. Vautherot and H. Laude, *Virology* **188** (1992) 666.
- [16] A.R. Fehr and S. Perlman, In: Maier HJ, Bickerton E, Britton P (eds.), *Coronaviruses. Methods in Mol. Biol.* **1282** (2015), Springer, pp. 1–23.p
- [17] B.W. Neuman, B.D. Adair, C. Yoshioka, J.D. Quispe, G. Orca and P. Kuhn, *J. Virology* **80** (2006) 7918.
- [18] D. Schoeman and B.C. Fielding, *Virology J.* **16** (2019) 69.
- [19] B.W. Neuman, G. Kiss, A.H. Kunding, D. Bhella, M.F. Baksh and S. Connelly, *J. Structural Biol.* **174** (2011) 11.
- [20] J. Alsaadi, IM. Jones, *Future Virology.* **14** (2019) 275.
- [21] C.K. Chang, M.H. Hou, C.F. Chang, C.D. Hsiao and T.H. Huang, *Antiviral Res.* **103** (2014) 39.
- [22] P.C. Woo, Y. Huang, S.K. Lau and K.Y. Yuen, *Viruses.* **2** (2010) 1804.
- [23] E.J. Snijder, P.J. Bredenbeek, J.C. Dobbe, V. Thiel, J. Ziebuhr and L.L. Poon, *J. Mol. Biol.* **331** (2003) 991.
- [24] C. Rothe, M. Schunk, P. Sothmann, G. Bretzel, G. Froeschl, C. Wallrauch, T. Zimmer, V. Thiel, C. Janke, W. Guggemos, M. Seilmaier, C. Drosten, P. Vollmar, K. Zwirgmaier, S. Zange, R. Wölfel and M. Hoelscher, *N. Engl. J. Med.* **382** (2020) 970.
- [25] L. Zou, F. Ruan and M. Huang, *N. Engl. J. Med.* **382** (2020) 1177.
- [26] G. Kampf, D. Todt, S. Pfaender, E. Steinmann, *Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents:* *J. Hosp. Infect.* (2020), pii: S0195–6701(20)30046–3.
- [27] WHO Situation Reports, <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/> Accessed 22 Feb (2020).
- [28] C. Huijun, G. Juanjuan, W. Chen, L. Fan, Y. Xuechen, Z. Wei, L. Jiafu, Z. Dongchi, X. Dan, G. Qing, L. Jing, Y. Huixia, H. Wei and Z. Yuanzhen. *The Lancet* **395** (2020) 809–815. doi: 10.1016/S0140-6736(20)30360-3.
- [29] R.J. de Groot, S.C. Baker, R. Baric, L. Enjuanes, A.E. Gorbalenya, K.V. Holmes, S. Perlman, L. Poon, P.J. Rottier, P.J. Talbot, P.C. Woo, J. Ziebuhr, A.M.I. King, E. Lefkowitz, M.J. Adams and E.B. Carstens, *International Committee on Taxonomy of Viruses, International Union of Microbiological Societies. Virology Division (eds.): Ninth Report of the International Committee on Taxonomy of Viruses*, Oxford: Elsevier (2011), pp. 806–28. doi:10.1016/B978-0-12-384684-6.00068-9.
- [30] N. Decaro, C. Tidona and G. Darai (eds.), *Betacoronavirus: The Springer Index of Viruses*, Springer (2011) pp. 385–401. doi:10.1007/978-0-387-95919-1_57.
- [31] Z.J. Cheng and J. Shan, *Novel coronavirus: where we are and what we know. Infection* **2020** (2019) 1–9, 10.1007/s15010-020-01401-y.
- [32] D. Forni, R. Cagliani, M. Clerici and M. Sironi, *Trends in Microbiology* **25** (2017) 35–48, doi:10.1016/j.tim.2016.09.001.
- [33] S.K. Lau, K.S. Li, A.K. Tsang, C.S. Lam, S. Ahmed and H. Chen, *J. Virology* **87** (2013) 8638–50. doi:10.1128/JVI.01055-13.
- [34] G. Simmons, P. Zmora, S. Gierer, A. Heurich and S. Pöhlmann, *Antiviral Res.* **100** (2013) 605–14, doi:10.1016/j.antiviral.2013.09.028.
- [35] M. Godet, R. L'Haridon, J.F. Vautherot and H. Laude, *Virology* **188** (1992) 666–75, doi:10.1016/0042-6822(92)90521-p.

- [36] P.S. Masters, "The molecular biology of coronaviruses", *Adv. Virus Res.* (Academic Press) **66** (2006) 193–292. doi:10.1016/S0065-3527(06)66005-3.
- [37] A.R. Fehr and S. Perlman, S (2015). "Coronaviruses: an overview of their replication and pathogenesis" In H.J. Maier, E. Bickerton and P. Britton (eds.). *Coronaviruses: Methods in Molecular Biology* **1282** (2015) 1–23, doi:10.1007/978-1-4939-2438-7_1
- [38] X. Li, M. Geng, Y. Peng, L. Meng and S. Lu, "Molecular immune pathogenesis and diagnosis of COVID-19", *J. Pharma. Anal.* **10** (2020) 102–108, doi:10.1016/j.jpha.2020.03.001. PMC 7104082. PMID 32282863.
- [39] Z. Zhao, Y. Wei and C. Tao, "An enlightening role for cytokine storm in coronavirus infection", *Clinic. Immun.* **222** (2021) 108615, doi:10.1016/j.clim.2020.108615.
- [40] N. Poyiadji, G. Shahin, D. Noujaim, M. Stone, S. Patel and B. Griffith, *Radiology* **296** (2020) E119–E120, doi:10.1148/radiol.2020201187.
- [41] S. Córdoba-Vives and G. Peñaranda, *Med. J. Costa Rica* **629** (2020).
- [42] S. Das and S Dhar, *Ind. J. Surg.* (2021) 1–2, doi:10.1007/s12262-021-03028-1.
- [43] C. Baruah, P. Devi, B. Deka B and D.K. Sharma, *Adv. Case Stud.* **3** (2021), doi:10.31031/AICS.2021.03.000555
- [44] H.D. Larsen, J. Fonager, F.K. Lomholt, T. Dalby, G. Benedetti and B. Kristensen, *Euro Surveillance* **26** (2021) 2100009, doi:10.2807/1560-7917.ES.2021.26.5.210009
- [45] "New COVID-19 Variants". Centers for Disease Control and Prevention, 28 June 2021 [First published 11 February 2020], Retrieved 15 July 2021.
- [46] E. Mahase, *BMJ* **371** (2020) m4944, doi:10.1136/bmj.m4944.
- [47] A.G. Harrison, T. Lin and P. Wang, *Trend. Immun.* **41** (2020) 1100–1115, doi:10.1016/j.it.2020.10.004.
- [48] P. Verdecchia, C. Cavallini, A. Spanevello and F. Angeli, *Eur. J. Inter. Med.* **76** (2020) 14–20, doi:10.1016/j.ejim.2020.04.037.
- [49] M. Letko, A. Marzi and V. Munster, (April 2020). *Nat. Microbio.* **5** (2020) 562–569, doi:10.1038/s41564-020-0688-y.
- [50] P.E. Marik, J. Iglesias, J. Varon and P. Kory, *Int. J. Immun. Pharma.* **35** (2021) 20587384211048026, doi:10.1177/20587384211048026.
- [51] N. Meunier, L. Briand, A. Jacquin-Piques, L. Brondel and L. Pénicaud, *Front. Physio.* **11** (2020) 625110, doi:10.3389/fphys.2020.625110.
- [52] Y.C. Li, W.Z. Bai, T. Hashikawa, *J. Med. Viro.* **92** (2020) 552–555, doi:10.1002/jmv.25728.
- [53] H. Yavarpour-Bali and M. Ghasemi-Kasman, *Life Sci.* **257** (2020) 118063, doi:10.1016/j.lfs.2020.118063.
- [54] J. Gu, B. Han and J. Wang, *Gastroenter.* **158** (2020) 1518–1519. doi:10.1053/j.gastro.2020.02.054.
- [55] K. Mönkemüller, L. Fry and S. Rickes, (May 2020). *Revista Espanola de Enfermedades Digestivas* **112** (2020) 383–388, doi:10.17235/reed.2020.7137/2020.
- [56] Y.Y. Zheng, Y.T. Ma, J.Y. Zhang and X. Xie, *Nature Reviews: Cardiology* **17** (2020) 259–260, doi:10.1038/s41569-020-0360-5.
- [57] C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao and Y. Hu, *Lancet* **395** (2020) 497–506, doi:10.1016/S0140-6736(20)30183-5.

- [58] "Coronavirus disease 2019 (COVID-19): Myocardial infarction and other coronary artery disease issues". UpToDate. Retrieved 28 September 2020.
- [59] M. Wadman, *Science* (2020), doi:10.1126/science.abc3208.
- [60] A.O. Eketunde, S.P. Mellacheruvu and P. Oreoluwa, *Cureus. Cureus, Inc.* **12** (2020) e9438, doi:10.7759/cureus.9438.
- [61] N. Dehingia, *Lancet: Global Health* **9** (2021) e14–e15, doi:10.1016/S2214-109X(20)30464-2.
- [62] "WHO Director-General's statement on the advice of the IHR Emergency Committee on Novel Coronavirus", World Health Organization.
- [63] R. Pansini and D. Fornacca, *Atmosphere* **12** (2021) 795, doi:10.3390/atmos12060795.
- [64] S. Comunian, D. Dongo, C. Milani and P. Palestini, *Int. J. Envir. Res. Pub. Health* **17** (2020) 4487, doi:10.3390/ijerph17124487.
- [65] J.L. Domingo, M. Marquès and J. Rovira, *A review: Envir. Res.* **188** (2020) 109861, doi:10.1016/j.envres.2020.109861.
- [66] A.B. Huntwork, *Cureus.* **13** (2021) e17829, doi:10.7759/cureus.17829.
- [67] H.R. Niazkari, B. Zibae, A. Nasimi and N. Bahri, *Neuro. Sci.* **41** (2020) 1667–1671, doi:10.1007/s10072-020-04486-3.
- [68] "Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19)", U.S. Centers for Disease Control and Prevention (CDC), 6 April 2020, Archived from the original on 2 March 2020, Retrieved 19 April 2020.
- [69] D.P. Oran and E.J. Topol, *EJ* (January 2021). "The Proportion of SARS-CoV-2 Infections That Are Asymptomatic : A Systematic Review", *Ann. Int. Med.* **174** (2021) 655–662, doi:10.7326/M20-6976; "Transmission of COVID-19", *Eur. Cent. Disease Prevent. Control*. Retrieved 6 December 2020; B. Nogrady, (November 2020). "What the data say about asymptomatic COVID infections", *Nature* **587** (2020) 534–535., doi:10.1038/d41586-020-03141-3.
- [70] Z. Gao, Y. Xu, C. Sun, X. Wang, Y. Guo, S. Qiu and K. Ma, "A systematic review of asymptomatic infections with COVID-19", *J. Microb. Immun. Infec.* **54** (2021) 12–16, doi:10.1016/j.jmii.2020.05.001.
- [71] D.P. Oran and E.J. Topol, "Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review", *Ann. Inter. Med.* **173** (2020) 362–367, doi:10.7326/M20-3012.
- [72] M.L. Adams, D.L. Katz and J. Grandpre, *Emerg. Infec. Diseas.* **26** (2020) 1831–1833, doi:10.3201/eid2608.200679.
- [73] A.H. Gupta, *The New York Times*, Retrieved 7 April 2020.
- [74] A.V. Dorn, R.E. Cooney and M.L. Sabin, *Lancet* **395** (2020) 1243–1244, doi:10.1016/S0140-6736(20)30893-X.
- [75] K. Batthyány, CLACSO, Retrieved 22 April 2021.
- [76] S. Bhaskar, A. Sinha, M. Banach, S. Mittoo, R. Weissert and J.S. Kass, *Front. Immun.* **11** (2020) 1648, doi:10.3389/fimmu.2020.01648.
- [77] E.A. Wastnedge, R.M. Reynolds, S.R. van Boeckel, S.J. Stock, F.C. Denison, J.A. Maybin and H.O. Critchley, *Physio. Rev.* **101** (2021) 303–318, doi:10.1152/physrev.00024.2020.

- [78] U. Ghoshal, S. Vasanth and N. Tejan, *Ind. J. Gastroenter.* **39** (2020) 236–242, doi:10.1007/s12664-020-01082-3.
- [79] "RNA Extraction", AssayGenie, *Archived* from the original on 6 May 2020, Retrieved 7 May 2020.
- [80] "How is the COVID-19 Virus Detected using Real Time RT-PCR?", IAEA, *Archived* from the original on 1 May 2020
- [81] "Curetis Group Company Ares Genetics and BGI Group Collaborate to Offer Next-Generation Sequencing and PCR-based Coronavirus (2019-nCoV) Testing in Europe", *GlobeNewswire News Room*, 30 January 2020, *Archived* from the original on 31 January 2020.
- [82] R. Kubina and A. Dziedzic, *Diagnostics* **10** (2020) 434, doi:10.3390/diagnostics10060434.
- [83] C.D. Russell, J.E. Millar and J.K. Baillie, *Lancet* **395** (2020) 473–475, doi: 10.1016/S0140-6736(20)30317-2.
- [84] J.P. Zhao, Y. Hu and R.H. Du, *Zhonghua Jie He He Hu Xi Za Zhi.* **43** (2020) E007
- [85] M.L. Holshue, C. Chas, S. Scott, K.H. Lofy, J. Wiesman, H. Bruce, C. Spitters, K. Ericson, S. Wilkerson, A. Ahmet, G. Diaz, A. Cohn, L. Fox, A. Patel, S.I. Gerber, L. Kim, S. Tong, X. Lu, S. Lindstrom, M.A. Pallansch, W.C. Weldon, H.M. Biggs, T.M. Uyeki and S.K. Pillai, *New England J. Med.* **382** (2020) 929–936, doi: 10.1056/NEJMoa2001191.
- [86] "Wear masks in public says WHO, in update of COVID-19 advice", *Reuters*, Retrieved 3 July 2020.
- [87] "Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission", *U.S. Centers for Disease Control and Prevention*, Retrieved 17 April 2020.
- [88] "Using face masks in the community – Technical Report" *ECDC*, 8 April 2020.
- [89] "Scientific Brief: Community Use of Cloth Masks to Control the Spread of SARS-CoV-2", *U.S. Centers for Disease Control and Prevention*, 10 November 2020.
- [90] T. Greenhalgh, M.B. Schmid, T. Czypionka, D. Bassler and L. Gruer, *BMJ* **369** (2020) m1435. doi:10.1136/bmj.m1435.
- [91] "What to Do if You Are Sick", *U.S. Centers for Disease Control and Prevention*, Retrieved 24 April 2020.
- [92] "Coronavirus Disease 2019 (COVID-19) – Prevention & Treatment", *U.S. Centers for Disease Control and Prevention*, Retrieved 11 March 2020.
- [93] M. Harris, T.G. Adhanom, T. Liu, M. Ryan, V.J. Mike, V. Kerkhove, D. Maria, I. Foulkes, C. Ondelam, C. Gretler, "COVID-19", *World Health Organization*, Retrieved 2020-03-29.
- [94] L. Hensley, *Global News*, Corus Entertainment Inc., Retrieved 2020-03-29.
- [95] R. Venske and A. Schwyzer (ed.). NDR Kultur (in German). *Norddeutscher Rundfunk*. *Archived* from the original on 2020-03-27. Retrieved 2020-03-27. (NB. Regula Venske is president of the PEN Centre Germany.)
- [96] C.Y. Johnson, L. Sun and A. Freedman, *The Washington Post*. *Archived* from the original on 2020-03-27, Retrieved 2020-03-11.
- [97] K. Pearce, *The Hub*. *Johns Hopkins University*, Retrieved 2020-03-29.
- [98] "Risk Assessment and Management". *Centers for Disease Control and Prevention*. 2020-03-22, Retrieved 2020-03-29.



Thai connections to Nobel and Science prizes

Safiqul Islam¹

Department of Mathematics, St. Theresa International College, Ongkarak, Nakhon Nayok, Thailand

Abstract: This research is a persistent effort to find out the possible reasons why some great Thai citizens as well as scientists missed the Nobel Prize but received major Scientific accreditation. Many great scientists worldwide have made significant contributions pertaining to science but not received any recognition yet. There has always been a thrust in Thailand to inculcate the scientific literacy through local wisdom, with emphasis on HM King Bhumibol Adulyadej's philosophy of sufficiency economy, moral infusion, and the Buddhism way of life.

Keywords: Nobel Prize; Thai Scientists; COVID-19 vaccine; NSTDA; TAST

1 Introduction

In 1895, Sir Alfred Nobel instituted the prizes for outstanding accomplishments in chemistry, physics, medicine or physiology, literature and later on for economics [1, 2]. The first prizes in Chemistry, Literature, Peace, Physics and Physiology or Medicine were given in the year 1901. Apart from general science and technology awards, there are several specific lists of awards that are given in various fields like agriculture, archeology, astronomy, aviation, biochemistry, biology, biomedical science, computer science, earth sciences, economics, engineering, environmental science, geography, geology, geophysics, mathematics, mechanical engineering, meteorology, motor vehicle, oceanography, ornithology, paleontology, psychology, science and technology awards for women, social sciences, space and technology, and so on.

Alfred Nobel was a pacifist with a pessimistic outlook towards mankind (Frängsmyr, 1966) [3]. We should never forget that hard work is a part of every laureate's journey towards the Nobel Prize. Failure is the only constant in every scientist's life. Each experiment has a risk, that is it might fail. Lack of technology might be a possible reason, or the theory wasn't correct, or simply because the experimental protocol was improper. This emotional investment of scientists is incomparable.

2 Thai Nobel connections

Although Thai researchers and writers are yet to be recognized by the Nobel Committee, Thailand has nevertheless participated in the nomination and awards process [4]. On the website of the Nobel Committee in Stockholm, we see that two nominations were made from Thailand for the Nobel Peace Prize. Both were concerned with the rights and welfare of children. The first, in 1928, was made by Prince Thewawongwarorathai (1883–1943), a grandson of HM King Mongkut (Rama

¹ Email: sofiqu001@yahoo.co.in



Fig. 1 Alfred Nobel [1883–1896]



Fig. 2 HH Prince Traidoss Prabandh [1883–1943]

IV). Also known as HH Prince Traidoss Prabandh, he served as Siamese Minister of Foreign Affairs. As such, he was involved in international matters. So in 1928, HH Prince Traidoss nominated for the Nobel Peace Prize Sir Robert Stephenson Smyth Baden-Powell. As all Thais interested in scouting know, Lieutenant General Baden-Powell (1857-1941) was a British Army officer and author of *Scouting for Boys*, an inspiration for the Scout Movement. Baden-Powell was also founder and first Chief Scout of the Boy Scouts Association and founder of the Girl Guides. According to the nomination by HH Prince Traidoss: Baden-Powell founded the Boy Scouts movement in 1907 and he organized the movement internationally. He and his sister Agnes founded the Girl Guides in 1910 (in the US Girls Scouts from 1912). Baden-Powell organized the Wolf Cubs in Great Britain (Cub Scouts in

the US) for boys under the age of 11 in 1916. The nominators emphasized the brotherly mentality and the non-militaristic character of the movement.

NSOT or Khana Luksuea Haeng Chat is The National Scout Organization of Thailand. HM King Rama VI established the scouting organization in Thailand in 1911 and among the charter members of the World Organization of the Scout Movement in 1922. HH Prince Traidos was aware of the importance of Baden-Powells contribution internationally and in the Kingdom. He was not alone, for in 1928, nine other prominent personalities from Switzerland, the UK, Japan, and other nations nominated Baden-Powell for the same award. Even so, he ultimately never received it.



Fig. 3 HRH Prince Vanna Vaidhayakara [1891-1976]

The other nomination from Thailand in the database of the Nobel Prize Committee occurred in 1963. In that year, the United Nations Children 's Fund (UNICEF) was nominated for the Nobel Peace Prize for helping the lives of children all over the world. The nomination was by HRH Prince Vanna Vaidhayakara, Prince of Naradhip Bhongseprabhan, known in the West as Wan Waithayakon (1891-1976), a Thai diplomat. HRH Prince Wan Waithayakon was elected President of the Eleventh Session of the United Nations General Assembly (1956-1957), while serving as Thailand's Permanent Representative to the United Nations. Like HH Prince Traidos Prabandh, he was also a grandson of King Rama IV. In 1963, other nominees from different European countries also suggested that UNICEF was worthy of receiving the Nobel Peace Prize. In 1965, the prize was indeed awarded to UNICEF for its promotion of brotherhood among the nations as a peace-factor of great importance.

As the website of UNICEF Thailand observes, despite economic advances in the Kingdom, huge disparities remain, and the benefits of economic progress have not been equally shared by all children in Thailand. This is particularly true for the children of ethnic minorities, migrants, refugees and the very poor. Several challenges continue to be confronted by UNICEF Thailand, we can appreciate HRH Prince Vanna Vaidhayakaras initiative over a half-century ago to recognize this important organization and its work. Since the Second World War, too, The

Nobel Prize and national politics there has been a steady migration of scientists responding to the pull of better research and economic opportunities afforded primarily in the United States and Western Europe.

It is a delicate question whether the authorities in any country are willing to actively help their scientists receive a Nobel Prize. Lobbying may be done with taste and honest means, though nobody is eager to go on record about what activities may be carried out in this respect. Recently, a noted science historian in Budapest was invited to prepare a report on whether it was feasible to facilitate creating another Nobel laureate in Hungary.

3 Great Thai citizens and scientists



Fig. 4 Sithiporn Kridakara [1883–1971]

Sithiporn Kridakara [5], known as Thailand's Farmer Prince was awarded the 1967 Ramon Magsaysay Award for Public service towards his efforts in the development of Thai agriculture. Born on April 11, 1883, Sithiporn studied in England for most of his early years. At 18, while studying mechanical engineering at City and Guild's Technical College, he returned back to his home country to help manage the family's lime-burning business.

He was the fourth son of His Royal Highness Krida Bhinihan, the Prince Naretraworit, grandson of King Mongkut, and nephew of King Chulalongkorn. Despite the royal blood, he developed a profound interest in agriculture. This interest aroused in him due to his wife's fragile health which necessitated the fresh air and open spaces of the countryside. Sithiporn was successful in propagating the Nicholson Yellow Dent variety of corn which he also encouraged other farmers to plant for animal feed. Starting 1950 corn was planted in place of rice as it was more favorable to land conditions. During 1980s, corn became one of Thailand's major exports. He played a major role in establishing an egg producers' association which made Thailand an exporter of eggs. The United Nations Food and Agriculture Organization (FAO) established the International Rice Commission in 1949, when Sithiporn was elected as chairman. He suggested for a research center for rice production during his meetings with the Rockefeller Foundation. As a result, the

International Rice Research Institute was establishment in Los Baños, Laguna in the Philippines.



Fig. 5 Phya Anuman Rajadhon [1888–1969]

One of modern Thailand's most remarkable scholars was Phya Anuman Rajadhon [6]. Besides being a self-trained linguist he was an anthropologist and ethnographer who became an authority on the culture of Thailand. His actual name was Yong Sathiankoset and Phraya Anuman Rajadhon was his noble title. He is well known by his family name, Sathiankoset, which is also his pen name. His prolific work as well as his interest in a multitude of culture-related fields, from folklore to sociology, set the foundations for an ever lasting cultural awareness among young Thai scholars. Inspired by nocturnal village spirits of Thai folklore, Phraya Anuman Rajadhon conducted a serious study of Thai folkloristics which were revealed in Thai films that have become classics.

At a time when much of the traditional culture was being overwhelmed by modernity, he observed Thai society with intrinsic details. He studied in depth the language, social norms, popular customs, oral tradition as well as the ethical system of the Thai people. He has worked at the Oriental Hotel in Bangkok during his early life. He has worked as a clerk at the Thai Customs Department where his friend Mr. Norman Mackay helped him to polish his broken English. He gathered knowledge for his research and compiled works on his own. Being interested in Thai popular culture, he recorded and described many of the ancient habits of Thais which would have been unnoticed had he not been put them down into his illustrative writings.

He wrote novels under the pen name Sethyankōsēt, better spelled as Sathirakoses. Phraya wrote works on important Thai cultural figures and penned the biography of Phra Saraprasoet (Trī Nākhapraphīp) (1889–1945), a notable author and commentator of Thai literature. He was acquainted with Phra Saraprasoet and both worked together as co-translators of many works. Among them notable was “The Pilgrim Kamanita”, a novel by Karl Adolph Gjellerup, a Danish Nobel laureate. It was about a young Indian merchant's seeking for truth and his encounter with Lord Buddha. The translation found its place in the textbooks

of the Thai secondary school curriculum and admired for its beautiful prose. He was recognized many years later when he received invitation to universities to give lectures. The Siam Society honoured him with the post of President. Social activist Sulak Sivaraksa, founder of the Sathirakoses-Nagapradeepa Foundation rightly described Phya Anuman Rajadhon as a National Hero, at the 100th year of his birth which was staged in 1988 by UNESCO.



Fig. 6 Sood Sangvichien [1907-1995]

Sood Sangvichien [7] was a Thai medical doctor and anatomist, who taught anatomy at the Siriraj Hospital Faculty of Medicine. He was a professor and served as head of the anatomy department and later dean of the faculty. He was particularly known for his pioneering works in archaeology and physical anthropology and made the first detailed studies of prehistoric skeletal remains in the 1960's.



Fig. 7 Rapee Sagarik [1922–2018]

Rapee Sagarik [8], better known as the “father of Thai orchidology”, was a Thai horticulturist, botanist and orchid expert. Rapee Sagarik was born on 4 December 1922 in Worachak Sub-district, Pom Prap Sattru Phai District, Bangkok. Rapee started primary education at Samsen Witthayakhan School and then in 1953, he moved to Satri Chulalak school until 1928. He studied at Saint Gabriel’s College and furthered his studies during 1931–1932 at the Yaowakumarn School under the Royal Patronage. During 1940–1985, he studied at the Kasetsart University Preparatory School (now Maejo University) at Maejo, Chiang Mai Province (which was established as a five-year bachelor’s degree program of Kasetsart University in 1943). In 1947, he graduated in pedology from the Faculty of Agriculture, Kasetsart University. He later received an honorary doctorate degree in Agricultural Innovation from Rangsit University on 23 February 2015.

Rapee became a full-time instructor of Kasetsart University, however, due to his passion for fieldwork, he chose to work at an agricultural experiment station in Mae Jo as a temporary employee. He conducted research on rice, vegetable and tobacco varieties. Meanwhile, he also conducted research on orchids using his own funds, an activity which would later become a fixture in his life. He was devoted to orchid research, and would become internationally recognized in the field of orchidology as one of its foremost experts. Having done research at the station for two years, he returned to government service as a full-time lecturer at Kasetsart University.

His work on research and promotion of orchids, as well as development as an export industry, made Thai orchids an important agricultural export product of Thailand. In recognition, Rapee received the Dushdi Mala Medal from King Bhumibol for agriculture work. He was named a professor in 1970. Rapee worked as the President of Kasetsart University, and as Deputy Minister of Agriculture and Cooperatives during tenure of Prime Minister Kriangsak Chamanan. He held many other positions, even after retiring. During the 2006 political crisis, he jointly signed a royal petition asking for the king’s intervention in naming a prime minister, and was a consultant to the People’s Alliance for Democracy. After 1990, he resigned from the various public and private positions he held, to turn to a peaceful and simple life, though he continued to accept invitations for lectures, especially in rural and youth development, focusing on morality and ethics.



Fig. 8 Rawi Bhavilai [1925–2017]

Rawi Bhavilai [9] was a Thai astronomer, writer and translator. Born in 1925, Professor Dr. Rawee Pawilai, at age 19, joined as faculty of Chulalongkorn University, Thailand, in the Astronomy Department and presided for 42 years. He served as a Professor at the Physics Department of the Faculty of Science, Chulalongkorn University, and was known for his writings on astronomy as well as philosophy and religion.

A member of Thailand's Royal Institute, Dr. Pawilai also served as President of the Thai Astronomical Society. Beyond his interest in studying the stars, Dr. Pawilai expanded into the literary world. He wrote as well as translated a wide range of books from science, astronomy, philosophy and children's literature. His translations included *The Prophet* by Kahlil Gibran as well as *Alice's Adventures in Wonderland* by Lewis Carroll. His efforts made it possible for many Thai readers to enjoy these classics for the first time. Pawilai has created a legacy in translating valuable literature for future generations (along with a nod to his love for the stars and space above).

He was a fellow of the Royal Society of Thailand. In 2007, Dr. Pawilai was honored with the title of National Artist of Thailand, for his written works. In 2018 he was honored with a Google Doodle. His research on solar radiation and the structure of the solar layer helped make him Thailand's most renowned astronomer. At the award ceremony at Chitlada Palace, he received a pin and commemorative plaque from HRH Princess Maha Chakri Sirindhorn. Expressing his gratitude at the honor, he revealed that his greatest satisfaction was in spreading knowledge through yet entertaining prose.



Fig. 9 Sippanondha Ketudat [1931–2006]

Sippanondha Ketudat [10] was a Thai nuclear physicist, educationist and technocrat. He served as a Professor at Chulalongkorn University and also as Secretary-General at Office of the National Education Commission, Minister of Industry and Minister of Education. He held seats on several university councils, including multiple chairmanships, and was an honorary fellow of the Royal Society of Thailand.

Smith Dharmasaroja [11] is a Thai government official. In 1998, while serving as a meteorologist, he predicted that an earthquake and tsunami "is going to occur for



Fig. 10 Smith Dharmasaroja [1937–Present]

sure”. He warned about tsunami but was not taken seriously. After the tsunami of December 2004, which killed over 200,000 people, he was recalled from retirement and handed over the charge of developing Thai and regional warning systems. While being chief of the National Disaster Warning Centre in Thailand, Dharmasaroja publicly announced that a solar eclipse could lead to natural disasters such as earthquakes and tsunamis in Thailand, depending on the time when the sun shall unleash its energy.

Shaiwatna Kupratakul [12] is a Thai theoretical physicist. Kupratakul received his early education in Nakhon Ratchasima. He attended Chulalongkorn University at the Faculty of Science for one-and-a-half years, from 1961–1962. In 1962, Kupratakul received a Columbo Plan scholarship, from the Australian Government to study physics in Australia. He graduated with a BSc (Honours) in Physics from Monash University in 1966, and a PhD (Physics), also from Monash University, in 1970. His major research interests included the energy band structures of noble metals, the pressure effects of noble metals on the energy of band structures, and solar energy.

Since returning to Thailand, Kupratakul has worked as a lecturer, university administrator, and educational development project committee member or leader. He has also written both non-fiction and fiction works with the view of educating people in the area of science. He met Isaac Asimov in New York in November 1977, and Arthur C. Clarke at Colombo, Sri Lanka, in February 1980. He was science inspired by the scientific writings of Isaac Asimov, Arthur C. Clarke, Jules Verne, H.C. Wells and Juntri Siriboonrod; the last of whom was proclaimed “Father of Thai Science Fiction”.

Kupratakul worked in the Physics Department, initially at Khon Kaen University from 1970–1982, and later at Srinakharinwirot University (Prasarnmit) from 1982–1999. He retired in 1999, but continues to give talks at universities, schools and for the public. He wrote science fiction (both short science stories and science novels), hosted radio and television programmes, and served as a committee member of several academic and national Councils. Kupratakul wrote and translated a variety of formats including articles, essays, short stories, novels and textbooks. These include both science and non-science subjects for audiences of all ages. More than 100 books, written or translated, have been published. Kupratakul assumed

the pen names of Shaikupt, Tachyon, Watanachai, and Sriwat and was nominated twice for the UNESCO Kalinga Prize in 1981 and 2004.



Fig. 11 Thida Thavornseth [1944–Present]

Thida Thavornseth (Thida Thawonset) [13] was a Thai Assistant Professor, microbiologist, pharmacist, and political activist. Thida was born in Surat Thani in Southern Thailand. She graduated from the Faculty of Pharmaceutical Sciences, Chulalongkorn University. She participated in the pro-democracy uprising of October 1973, that ended the military dictatorship. Thida is the chairperson of the United Front for Democracy Against Dictatorship (UDD), whose supporters are commonly known as the Red Shirts.



Fig. 12 Pichaet Wiriyachitra [1944–Present]

Pichaet Wiriyachitra [14] was a Professor of chemistry at Prince of Songkla University, who obtained his Ph.D, Organic Chemistry from the University of Tasmania. He followed this with a Post-doctoral Fellowships at the University of Connecticut and University of Pennsylvania. Pichaet also became the Vice President and Dean of Graduate School of Songkla University. He was a Guest

Scientist at the Japan Society for the Promotion of Science as well as the German Cancer Research Center.

He has specialized in the development of pharmaceuticals from natural products, particularly Xanthone from Mangosteen. Currently he is the Chairman and CEO of Asian Phytochemicals Public Co., Ltd., and also President of both the Asian Life Co. Ltd. and Green Gold Co., Ltd. He leads a scientific team at the Mangosteen Research and Development Center (Thailand) called Operation BIM. Their research has proven that the beneficial effects of the plant are due to the substance known as *Garcinia mangostana* (GM-1), the scientific name for mangosteen. The GM-1 molecule lowers the elevated level of interleukin 1 and significantly raises the amount of interleukin 2 cytokines. This condition balances the body immune system thereby making it stronger against pain, fever, inflammation, diarrhea, bacterial and viral infection, atherosclerosis, aging, arthritis, mouth ulcer, intestinal ulcer, stomach ulcer and cancer-as tested successfully in laboratory.

Combining the extracts of five Thai fruits and grains, a formula has been made that reduces the effects of the cytokine which is the main cause of death by respiratory viruses or airborne viruses. The researchers believe that this formula can help prevent the fatality from all types of respiratory viruses, like H1N1 and the possible mutated strains in the future.



Fig. 13 Yong Poovorawan [1950–Present]

Yong Poovorawan [15] was a medical professor in pediatric hepatology at the Faculty of Medicine of Chulalongkorn University in Bangkok, Thailand. He received his Doctor of Medicine in 1974 from Chulalongkorn University. Yong trained in pediatrics at the Chulalongkorn University Faculty of Medicine and completed board certification by the Medical Council of Thailand in 1978. He was subsequently accepted as a faculty member, and received a research fellowship grant at the hepatology department at King's College Hospital Medical School during 1983-84. He has since worked continuously at Chulalongkorn, mostly focusing on teaching and research, and obtained professorship in 1990. Yong has served as the head of the faculty's Viral Hepatitis Research Unit and Molecular Biology Research Unit since 1992 and 1996, respectively. Since his medical school, he has held a deep interest in research. He first published in national journals during his first year of residency, and began publishing internationally in 1989, with his work on hepatitis

B vaccination. He is author or co-author of over 400 publications in the fields of gastroenterology, hepatology, and virology indexed by the PubMed database, with over 17,000 citations and an h-index of 61 as calculated by Google Scholar.

His works originally has emphasis on the fields of pediatric hepatology and viral hepatitis, and applications to the Thai health-care system in particular. Later on he did research on virology studies. Yong is widely recognized for his work on genetic sequencing as well as detection of the H5N1 avian influenza virus in Thailand, which outbreak in the beginning of 2004. His works received outstanding research awards from the Thailand Research Fund in 2004 and the National Research Council in 2006. Yong served on the editorial board of the Journal of Pediatrics, in addition to other national publications.



Fig. 14 Kanchana Kanchanasut [1951–Present]

Kanchana Kanchanasut [16] is a Thai computer science Professor at the Asian Institute of Technology. Kanchanasut graduated with a Bachelor of Science in math and an additional diploma in computer science, from the University of Queensland in 1974. She complete her a Master of Science from University of Melbourne in 1979 and later returned to Melbourne where she received the Doctor of Philosophy in 1991. The first server in Thailand was hosted and connected to the Internet. Kanchanasut also registered Thailand's country code top-level *domain.th* in 1988. The first Thai person to use email was Kanchanasut. She was included into the Internet Hall of Fame in 2013 and rightly awarded the Jonathan B. Postel Service Award in 2016.

Banchob Sripa is a Thai scientist, Professor and Head of the Tropical Disease Research Laboratory (TDRL) at Khon Kaen University in Khon Kaen, Thailand. He is also the head of the World Health Organization Collaborating Centre for Research and Control of Opisthorchiasis. It is an infectious parasitic disease caused by the Southeast Asian liver fluke. The disease is endemic in northeastern Thailand and other portions of the Mekong River basin. He has worked for the Asian Neglected Tropical Disease Network as it's coordinator. He received a Doctorate in tropical health from the University of Queensland, Australia and in 2013 the Outstanding Scientist Award from the Foundation for the Promotion of Science and Technology. An opisthorchiasis control program [17] known as the "Lawa model"



Fig. 15 Banchob Sripa [1958–Present]

was initiated in 2007 by the Thailand Development Research Institute (TDRI) under Banchob. An EcoHealth approach was used in the program which has been more successful than earlier control programs. The program operates in 12 villages surrounding the Lawa Lake south of Khon Kaen. The liver fluke infection rate has declined to less than 10 percent from an average of 60 percent since the start of the program. Banchob has published more than 200 peer-reviewed scientific articles and eight book chapters in English.



Fig. 16 Chavalit Vidthayanon [1959–Present]

Chavalit Vidthayanon [18] is a Thai ichthyologist and senior researcher of biodiversity of WWF Thailand. He graduated from Bangkok Christian College and graduated in marine biology from Kasetsart University and Chulalongkorn University. Vidthayanon received a Ph.D. in fishery biology from the Tokyo Fisheries University (now's Tokyo University of Marine Science and Technology), Japan. He has been working on aquatic biodiversity studies in Southeast Asia since 1983. He has collaborated with leading ichthyologists both Thais as well as foreigners like Kittipong Jaruthanin, T.R. Roberts, H.H. Ng and Maurice Kottelat etc. He has studied taxonomy and many of the newly discovered freshwater species in the world (many were found in Mekong Basin). These included *Amblypharyngodon*

chulabhornae, *Himantura kittipongi*, *Pangasius conchophilus*, *P. myanmar*, *Pao palustris*, *Pseudeutropius indigens*, *Schistura pridii* etc. He has specialized in Thai freshwater catfishes. In addition, he is also an instructor on ichthyology and zoology at several educational institutions in Thailand such as Mahasarakham University, Chulalongkorn University, Kasetsart University etc.



Fig. 17 Anavaj Sakuntabhai [1962–Present]

Anavaj Sakuntabhai [19] is a researcher specializing in human genetics of infectious diseases, notably malaria and dengue. Anavaj Sakuntabhai graduated in 1987 as a medical doctor and obtained his PhD in human molecular genetics from the University of Oxford in 1999. During 2000 he worked in Institut Pasteur as a senior scientist and in 2007 became the head of the laboratory of Genetics of Human Response to Infections. In 2010 he also became the head of the Functional Genetics of Infectious Diseases Unit.

He worked as a principal investigator in one of the four consortial projects of the MalariaGEN consortium. It represented a global community of researchers working together to integrate epidemiology with genome science and financed by the Bill and Melinda Gates Foundation. He is a partner of a Wellcome Trust financed project on the human genome wide screening for dengue susceptible genes. He is a principal investigator of a French initiative to tackle the disease burden under ever changing environments. He is a coordinator of the European FP7 project on DENFREE (Dengue Framework for Resisting Epidemics in Europe). The project aims to find the causative agents for dengue transmission and dengue epidemics. It also estimates the risk of spreading DENV to uninfected areas, especially in Southern Europe where susceptible vectors exist.

In 1999, Sakuntabhai discovered a gene which was responsible for Darrier disease. In 2005 he found a variant on a promoter of DC-SIGN associated with gene expression and outcome of dengue infection. In 2009, he participated in the finding of positive selection of G6PD (glucose 6 phosphate dehydrogenase) and its effect on *Plasmodium vivax*. The work highlights the significant effect of *P. vivax* on human health, one hitherto neglected. His recent research has shown that both genet

gene and gene to environmental interactions play a vital role in susceptibility to malaria and dengue.



Fig. 18 Kesara Margrét Anamthawat-Jónsson [Unknown–Present]

Kesara Margrét Anamthawat-Jónsson [20] is professor of botany and plant genetics at the Faculty of Life and Environmental Sciences, School of Engineering and Natural Sciences, University of Iceland. Her career began in Iceland in January 1982, at the Agricultural Research Institute in Keldnaholt in Reykjavik (now part of the Agricultural University of Iceland). In 1988 when she went to UK for her PhD studies. She established chromosome techniques to study birch trees and various other Icelandic plant species. Kesara also received training abroad on plant chromosome preparation methods at the University of Helsinki and animal cytogenetics at the School of Veterinary Science, University of Guelph. After completing her PhD in UK, she came back to work as a research scientist at this institute (1992–1996) and focussed on the genetics of birch trees, while initiating her own study of lyme grass in Iceland. For barley, she used molecular cytogenetic techniques to map retro-elements on chromosomes. She has collaborated with and supervised a number of PhD students in the genomic identification of several perennial Triticeae species. Kesara has studied the molecular genetic diversity of Icelandic lyme grass (*Leymus arenarius*), traced the genomic origin and has identified the genome composition of this genus. Since 2014, she has served as president and chairman of the Nordic Microscopy Society (SCANDEM). With the help of her colleagues, she organized the annual SCANDEM conference at the University of Iceland twice, in 2009 and 2017. Kesara has also joined the UK's Royal Microscopical Society and served a 3-year term on the RMS Council. In January 2019, she was elected FRMS fellow of the society. In appreciation of her academic service to the country, she was bestowed with The Highest Order of the White Elephant, Companion.

Yupa Hanboonsong [21] is a Thai entomologist, specializing in entomophagy (the use of insects as food). Hanboonsong received her PhD from Lincoln University, New Zealand. She currently works as an Associate Professor in the entomology department at Khon Kaen University. The effects on Thailand of the 1997 Asian financial crisis moved Hanboonsong great for which she trained rice farmers in



Fig. 19 Yupa Hanboonsong [Unknown–Present]

remote areas of the country to farm crickets as a cheap and plentiful source of nutrition. She has co-authored several reports on insect farming for the United Nations Food and Agriculture Organization (FAO). In 2003, she did research on Edible insects in Lao PDR and worked on building the tradition to enhance food security”.

4 Modern Thai scientists

There are at least eight Thai Scientists who have made considerable impact with their research. Pimchai Chaiyen [22] has won the 2003 L’Oréal Thailand For Women in Science Award. In 2017 she received the L’Oréal Woman Scientist Crystal Award for her research into a cleaner way to produce chemicals. For her research on environmentally friendly nanocatalysts, Pussana Hirunsit has won the 2017 L’Oréal-UNESCO For Women in Science National Award. For her work on powder metallurgy, Anchalee Manonukul received the 2017 L’Oréal Woman Scientist Crystal Award. It is a special award that commemorates the 15th anniversary of the L’Oréal-UNESCO for Women in Science Awards in Thailand. The 2017 Young Scientist Award for the Foundation for the Promotion of Science and Technology under the Patronage of His Majesty the King, went to Varodom Charoensawan for his bioinformatics research. Marisa Ponpuak received the 2017 L’Oréal-UNESCO For Women in Science Fellowship for her research on autophagy. It was aimed at finding new drugs for malaria and tuberculosis. Napida Hinchiranan was awarded the 2017 L’Oréal-UNESCO For Women in Science Fellowship. Her studies on using natural rubber were useful to create value-added products. David Ruffolo received the 2017 Outstanding Scientist Award from the Foundation for the Promotion of Science and Technology under Royal Patronage for his research on global radiation and cosmic rays and prediction of the effects of solar storms on Earth.

We should also make special reference of Ngamta “Natalie” Thamwattana who is a Thai mathematician and works in Australia as a Professor of Applied Mathematics at the University of Newcastle (Australia). In 2014 she won the J. H. Michell Medal of ANZIAM for her “pioneering contributions in the areas of granular materials and nanotechnology”. In her early career due to high test scores in science and mathematics, she earned a government scholarship with full tuition and, later,

support for doctoral studies abroad. She received her Ph.D. at Wollongong in 2004 under the guidance of James Murray Hill. After completing her studies, she returned the money received from her Thai scholarship. She went to Australia to join as a Wollongong faculty and founded the Nanomechanics Group there. In 2018 she moved to University of Newcastle (Australia) to take up a position as Professor of Applied Mathematics.

5 Thai scientists begin COVID-19 vaccine trials on monkeys

Thai scientists [23] have begun testing a vaccine against the corona virus on monkeys after positive trials in mice. Researchers have moved testing of the vaccine to monkeys and hoped to have a “clearer outcome” of its effectiveness by September’2020. COVID-19 vaccine testing is being done at Chula Vaccine Research Center. Thailand wants to be one of the countries to have a vaccine ready for use by the human race. COVID-19 is the disease caused by the novel corona virus and more than 100 potential vaccines are being developed, but vaccine would take at least 12 months to effect. The Thai vaccine is being developed by the National Vaccine Institute. The Department of Medical Science and Chulalongkorn University’s vaccine research centre is working towards it’s success.



Fig. 20 The Thai vaccine using M-RNA, prompting body cells to produce antigens. Molecules on the surface of viruses bring the immune system into action. A laboratory baby monkey being examined by employees at the National Primate Research Center of Thailand at Chulalongkorn University in Saraburi.

6 Final Remarks

Known for its resorts and Buddhist temples, Thailand is also a regional centre of research and development and high-tech manufacturing [24]. It’s the world’s second-largest exporter of hard disk drives and a major centre for car production.

Thailand has contributed to basic science which has grown in recent years, with its researchers doubling their output in physical sciences journals within the index between 2012 and 2015. A major player is that the state-backed National Science

and Technology Development Agency (NSTDA). Established in 1991, it supports centres of excellence in gene-splicing, biotechnology, electronics and nanotechnology.

Thai scientists like a chemist at Chulalongkorn University, Patchanita Thamyongkit, have been raising the profile of home-grown research. Her work on the chemistry behind solar cells use organic compounds, referred to as porphyrins, for which she received the Theoretical Physics prize in 2013 from Abdus Salam International Centre. She also received the LOreal-UNESCO accolade in 2014 for ladies in science. However, the country suffers from a paucity of researchers and funding. “Thailand is focused on cultivating a new generation of young scientists by promoting a number of fields which include biotechnology, biomedical devices, robotics and the Internet of Things”.

The Thai Academy of Science and Technology (TAST) was established in 1997 [25]. It was organized by a group of scientists and technologists whose works have been continuously recognized and whose experiences and interests are vital to the development of the nation as a whole. TAST is a “non-governmental agency”. This is to ensure that there is no bias in giving recommendations to national organizations, government and the public as a whole. TAST realizes that matters concerning science and technology have a profound impact on the nation. Therefore, it has made this its duty and priority to select issues or matters that are currently within the eyes of the general public, and perform careful analyses, doing research, and formalize plans for the longer term development of the nation. The academy was established and registered with the Bangkok registrar office and was endorsed by the Permanent Secretary, Ministry of Interior on November 5, 1997.

Undoubtedly the cases discussed above concern Thai scientists who carried out outstanding work deserving Nobel Prize. One may suspect that Nobel prizes which epitomize the achievement of excellence as per the vision and norms of western civilization are hard to win by scientists from other nations, particularly from third world countries, in spite of the fact according to Nobel’s will in awarding the prizes no consideration be given to the nationality of the candidate. There would have been numerous deserving Nobel Laureates if the entire history of Thailand is taken into consideration. It is generally believed that to be worthy of the prize scientists from Thailand have to stand out distinctly much above his western counterpart. But such a view is perhaps too simplistic. Even in the western world there have been a number of cases where Nobel prizes were not awarded to very deserving cases. Confining only to physics, some of the glaring omissions (not in any particular order) are: Thomas Alva Edison (Inventor of many gadgets including telegraph, movies, electric bulb etc), Thomas Tesla (Electromagnetism), Lise Meitner (nuclear fission), Chien-Shiung Wu (Parity non-conservation), Yuval Neeman (Particle physics), George Zweig (quark composition of particles), Fred Hoyle (Astrophysics), Jocelyn Bell Burnell (Radio pulsars), George Gamow (Theory of Cosmic Microwave Background radiation), Freeman Dyson (quantum field theory), Robert Oppenheimer (Theoretical physics), Sidney R. Coleman (Particle physics).

The debate as to why most Thai citizens as well as Scientists missed the Nobel is left open to all audiences and Thais at large. Let’s hope for a better world where scientist’s shall be properly judged as they spent most of their times for the welfare of people and always try for a better improvement and quality of life.

Acknowledgement

I am very much grateful to the editor Professor Saibal Ray for illuminating suggestions that have significantly improved the work in terms of research quality and presentation. I am thankful to Professor Dwiptendra Bandyopadhyay of STIC for his immense research guidance throughout. I am thankful to my mother Mst. Momena Begum, who has always been a source of my inspiration. The paper is compiled during the hard time when mankind is facing a great challenge to COVID-19. Let's all hope that science succeeds over all, in this greatest struggle for existence.

References

1. Google and Science Magazines.
2. https://en.wikipedia.org/wiki/Alfred_Nobel.
3. T. Frängsmyr, *The Royal Swedish Academy of Sciences, Alfred Nobel-Life and Philosophy* (1996). [http://www.nobelprize.org/alfred_nobel/biographical/articles/frangsmyr/].
4. <http://203.131.219.167/km2559/2017/10/29/thailand-and-the-nobel-prize/> Thailand and the Nobel Prize.
5. C.C.A. Balgos, "Nilawan Pintong", *Great Men and Women of Asia: Ramon Magsaysay Awardees from Southeast Asia 1958-1973* (2007).
6. F.K. Charles, K. William and S. Sulak, *Phya Anuman Rajadhon: A Reminiscence, Sathiankoset-Nakhapraphip Foundation* (1973).
7. V. Subhava, S. Pramankij and W.G. Solheim, "SOOD SANGVICHIE, 1907-1995". *Asian Perspectives*, **36** (2), 260-264 (1997).
8. https://en.wikipedia.org/wiki/Rapee_Sagarik
9. https://en.wikipedia.org/wiki/Rawi_Bhavilai
10. Fry G. W., Nieminen G. S. and Smith H. E., *Historical Dictionary of Thailand* (3, revised ed.). Scarecrow Press p. 281 (2013).
11. https://en.wikipedia.org/wiki/Smith_Dharmasaroja
12. https://en.wikipedia.org/wiki/Shaiwatna_Kupratakul#cite_note-1
13. https://en.wikipedia.org/wiki/Thida_Thavornseth
14. https://en.wikipedia.org/wiki/Pichaet_Wiriyachitra
15. https://en.wikipedia.org/wiki/Yong_Poovorawan
16. https://en.wikipedia.org/wiki/Kanchana_Kanchanasut
17. B. Sripa, S. Tangkawattana and T. Sangnikul, "The Lawa model: A sustainable, integrated opisthorchiasis control program using the EcoHealth approach in the Lawa Lake region of Thailand". *Parasitology international*, **66** (4): 346-354 (2017).
18. https://en.wikipedia.org/wiki/Chavalit_Vidthayanon#cite_ref-1
19. https://en.wikipedia.org/wiki/Anavaj_Sakuntabhai
20. https://en.wikipedia.org/wiki/Kesara_Margrét_Anamthawat-Jónsson
21. https://en.wikipedia.org/wiki/Yupa_Hanboonsong
22. <https://www.asianscientist.com/2018/12/features/as-100-thailand-science-technology-researchers/>
23. <https://www.ndtv.com/world-news/covid-19-thailand-begins-coronavirus-vaccine-trials-on-monkeys-2234135>
24. T. Hornyak, *Thailand's basic science grows despite limited resources*, nature index, 24 Jan (2017).
25. <https://www.interacademies.org/13602/Thai-Academy-of-Science-and-Technology-TAST>.



Nobel Prize 2021: Physics

A. DeBenedictis ¹

*The Pacific Institute for the Mathematical Sciences, and Simon Fraser University,
Burnaby, B.C. V5A 1S6, Canada*



Syukuro Manabe (b. 1931), Ph.D. 1958, Tokyo. Princeton University, USA.

Klaus Hasselmann (b. 1931), Ph.D. 1957, Göttingen. Max Planck Institute for Meteorology, Hamburg, Germany.

Giorgio Parisi (b. 1948), Ph.D. 1970, Rome. Sapienza University of Rome, Italy.

Ill. Niklas Elmehed © Nobel Prize Outreach (<https://www.nobelprize.org/press-images-for-media/>)

On October 5, 2021 the Royal Swedish Academy of Sciences announced the winners of the 2021 Nobel Prize in Physics. The award recipients were Klaus Hasselmann of the Max Planck Institute for Meteorology in Hamburg, Germany, Syukuro Manabe of Princeton University, USA, and Giorgio Parisi of Sapienza University of Rome, Italy.

Hasselmann and Manabe each received one-quarter of the prize for “the physical modelling of Earth's climate, quantifying variability and reliably predicting global warming”. Parisi received the other half of the Nobel prize for “the discovery of the interplay of disorder and fluctuations in physical systems from atomic to planetary scales” [1]. Although at first-glance it may seem that the two fields are not directly related, both areas involve the study of complex chaotic systems which are notoriously difficult to study over long time periods. Manabe and Hasselmann's work studied complex systems on the larger scale, and Parisi's work on the small scale, but can be applied to larger scales.

In the 1960s Syukuro Manabe developed models which illustrated that increased carbon dioxide content in the atmosphere leads to increased atmospheric temperatures. He was also a pioneer in exploring the non-trivial interplay between radiation balance and the vertical transport of air masses and his work is considered foundational in modern climate modelling. Hasselmann's work studied foundational issues which help today's scientists better understand Earth's climate change, one of the most pressing issues today. From his work one can identify specific clues indicating that natural phenomena as well as human activity can have significant effect on the climate. Like Manabe, Hasselmann's work has also been used to show that the increased carbon dioxide content in the atmosphere is increasing the global temperature and that human emissions are contributing to this.

Giorgio Parisi's share of the Nobel prize is related to his studies of spin glasses. Spin glasses are complicated systems of interacting atoms which tend to generally be disordered (have no discernible pattern) and this disorder makes them difficult to study. Parisi showed that properties exist in the possible configurations of such systems that allows one to classify and sort the systems into partially similar states (referred to as replicas). The problem then becomes one of essentially studying how one such state can be transformed into another such state. Although this may not seem closely related to climate science this concept has wide application to other complex systems such as biology and weather. Like spin glasses you there also have a large number of interacting quantities which are disordered.

[1] The Nobel Prize in Physics 2021. NobelPrize.org. Nobel Prize Outreach AB 2021. Wed. 3 Nov 2021.
<<https://www.nobelprize.org/prizes/physics/2021/summary/>>


¹ Email: adebened@sfu.ca



Nobel Prize 2021: Physiology/Medicine

Soham Ray ¹

Department of Biology, Tomsk State University, Lenin Ave, 36 Tomsk, Tomsk Oblast 634050, Russia



[Nobel Prize in Physiology or Medicine 2021 - Lindau Nobel Laureate Meetings \(lindau-nobel.org\)](https://lindau-nobel.org)

The 2021 Nobel Prize in Physiology or Medicine was awarded jointly to David Julius and Ardem Patapoutian “for their discoveries of receptors for temperature and touch” on Monday, 4 October 2021 by the Nobel Assembly at Karolinska Institutet. Independently of one another, both David Julius and Ardem Patapoutian used the chemical substance menthol to identify TRPM8, a receptor that was shown to be activated by cold.

Ardem Patapoutian is an American molecular biologist age 54 years and born to an Armenian family in Beirut, Lebanon. His father, known by the pen name Sarkis Vahakn, is a poet and an accountant. His mother, Haykuhi Achemian, was the principal of an Armenian school in Beirut. He has a brother and a sister. He enrolled at the American University of Beirut for a year before immigrating to the United States in 1986. His academic career can be summarised as follows:

- B.S. degree in cell and developmental biology from the University of California, Los Angeles in 1990;
- Ph.D. degree in biology from the California Institute of Technology in 1996, guided by Barbara Wold;
- Post doctorate at the University of California, San Francisco guided by Louis F. Reichardt Assistant professor at the Scripps Research Institute in 2000;
- Additional research position for the Novartis Research Foundation from 2000 to 2014;
- Investigator for the Howard Hughes Medical Institute (HHMI) since 2014.

¹ Email: raysohamjoy@gmail.com

He and his co-workers found a cell line that gave off a measurable electric signal when individual cells were poked with a micropipette. Then they identified a single gene which upon gene silencing turned the cells insensitive to poking with the micropipette. Through further investigations two entirely unknown mechanosensitive ion channels Piezo1 and Piezo2 were discovered. Just like when poked with a micropipette, they are activated by the exertion of pressure on cell membranes. Piezo2 ion channel is essential for the sense of touch, play a role in proprioception (sensing of body position and motion). Both Piezo1 and Piezo2 channels have been shown to regulate physiological processes like blood pressure, respiration and urinary bladder control.

Two of his most important publications in this field were:

- (i) Kim, Sung Eun; Coste, Bertrand; Chadha, Abhishek; Cook, Boaz; Patapoutian, Ardem (February 19, 2012). "The role of Drosophila Piezo in mechanical nociception", *Nature* **483** (7388) 209–212; doi:10.1038/nature10801
- (ii) Ranade, Sanjeev S.; Woo, Seung-Hyun; Dubin, Adrienne E.; Moshourab, Rabih A.; Wetzel, Christiane; Petrus, Matt; Mathur, Jayanti; Bégay, Valérie; Coste, Bertrand; Mainquist, James; Wilson, A. J. (December 2014). "Piezo2 is the major transducer of mechanical forces for touch sensation in mice", doi:10.1038/nature13980

David Jay Julius is an American physiologist aged 66 and born to a family with Russian descent in New York, USA. His father was an electrical engineer and mother an elementary school teacher. He has two brothers. His academic career can be summarised as follows:

- Undergraduate degree from Massachusetts Institute of Technology in 1977;
- Ph.D. degree at the University of California, Berkeley in 1984, under joint supervision of Jeremy Thorner and Randy Schekman;
- Post doctorate at Columbia University in 1989, under the supervision of Richard Axel.

Julius was interested in serotonin receptors and its relation with psilocybin mushrooms, which questioned him how things from nature interact with human receptors. He and his co-workers created a library which included a DNA fragment encoding the protein capable of reacting to capsaicin. After individual genes were expressed in cultured cells, a single gene was identified that was able to make cells capsaicin sensitive. Further investigations revealed that this new gene encoded a novel ion channel protein with ability to respond to heat. The newly discovered capsaicin receptor was named TRPV1.

Three of his most important publications in this field were:

- (i) Bautista, Diana M.; Siemens, Jan; Glazer, Joshua M.; Tsuruda, Pamela R.; Basbaum, Allan I.; Stucky, Cheryl L.; Jordt, Sven-Eric; Julius, David (July 12, 2007). "The menthol receptor TRPM8 is the principal detector of environmental cold", *Nature* **448** (7150): 204–208, doi:10.1038/nature05910. ISSN 1476-4687.
- (ii) Jordt, Sven-Eric; Bautista, Diana M.; Chuang, Huai-Hu; McKemy, David D.; Zygmunt, Peter M.; Högestätt, Edward D.; Meng, Ian D.; Julius, David (January 15, 2004). "Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1", *Nature* **427** (6971): 260–265, doi:10.1038/nature02282.
- (iii) Liao, Maofu; Cao, Erhu; Julius, David; Cheng, Yifan (December 5, 2013). "Structure of the TRPV1 ion channel determined by electron cryo-microscopy", *Nature* **504** (7478): 107–112, doi:10.1038/nature12822.

Reference: <https://www.nobelprize.org/prizes/medicine/2021/press-release/>



BOOK REVIEW

Snehamoy Datta - His Scientific Work in International Context


Rajinder Singh

Shaker Verlag, Düren, Germany/2021

Price: 21.90 Euro; Pages: 123

Hardev Singh Virk ¹

Professor of Eminence, SGGS World University, Fatehgarh Sahib, India



¹ Email: hardevsingh.virk@gmail.com

Rajinder Singh of University of Oldenburg, Germany, has created a sort of record in tracing the history of science in India. His focus remains on the Calcutta School, in particular, the Scientists of Golden era of Indian Science. The present volume is devoted to Snehamoy Datta (SD), an ignored scientist, whose worth is revealed by the author. Prof. AK Singhvi has paid high tributes to the author in his Foreword: "I also seized this opportunity to acknowledge and applaud Dr. Singh's efforts in bringing alive, the stories of unsung heroes of Indian science. I have truly admired his effort in this direction".

The author writes about SD in his Introduction: "J.C. Bose, the discoverer of the short-wave is considered as one of the initiators of the modern physics in India. His student, Snehamoy Datta (1894-1955), belongs to the 'Golden era of Indian Physics', that is, the first three decades of the 20th century". Then the author reveals the purpose of writing this book: "To the best of my knowledge, S. Datta's biography does not exist. The present book is written to fill the gap".

Chapter 1 narrates the salient features of life of SD: "Snehamoy Datta was born on Oct. 20, 1894, in Sabhar, a small village in Dacca (Dhaka), now in Bangladesh. In 1913, he graduated from the University of Calcutta. For his extraordinary achievement, he won the Woodrow scholarship. Datta joined the Presidency College in Calcutta, the only place where post-graduate studies were pursued in those days. In 1915, Snehamoy Datta was declared second in order of merit in M.Sc. Physics".

He won the Premchand Roychand Studentship to visit U.K. for higher studies and began his research career under the astrophysicist Alfred Fowler FRS. SD received D.Sc. from the University of London for his work: "1. On the spectra of the alkaline earth fluorides and their relation to each other. 2. The spectrum of beryllium fluoride. 3. The vacuum arc spectra of sodium and potassium. 4. The absorption spectrum of potassium vapour". On return to India in 1922, SD joined Presidency College Calcutta to teach Physics.

Chapter 2 describes the research activity of SD in UK and Germany. He first investigated the Selenium behaviour with temperature: "Transformation takes place at all temperatures. The various modifications may be regarded as maintaining a sort of dynamic equilibrium amongst themselves, the quantity of each variety depending on the particular temperatures". According to his fellowship condition, SD changed his field of research to Spectroscopy and started working under Alfred Fowler. He made new discoveries in the solar spectra. In his own words: "The presence of potassium in the Sun has been established, and some additional sodium lines have been identified with solar lines".

His contributions to the spectra of the alkaline earth fluorides (magnesium, calcium, strontium and barium) need to be highlighted as he found several new bands. His experiments established:

- (i) Nine series of bands in the spectrum of magnesium fluoride;
- (ii) Four new series for calcium fluoride in the ultra-violet region;
- (iii) Four new series for strontium fluoride in the ultra-violet and a very weak one in the red region.

His association with J. Franck in Germany resulted in discovery of the broadening of nitrogen positive bands in presence of bromine vapours.

Chapter 3 gives detailed description of SD's efforts to create absorption spectroscopy laboratory in Presidency College, Calcutta. He investigated band spectra of Nitrogen, and studied the absorption spectra of potassium, sodium and rubidium at moderate pressure. His other experimental investigations include: "Vacuum arc spectra of rubidium and lithium; Identification of the sun-spots line at λ 6708 Å; A new method to determine the ionization voltage of elements, and Characteristics of the long and short spectral lines in copper, silver, zinc and iron spectra". He was father of absorption spectroscopy in India and his research was published in international journals of repute.

In **Chapter 4**, author deals with the new assignment of SD as the Principal of Rajshahi Government College (1940-1945). He started applications of spectroscopy to areas of veterinary science and in printing industry. SD was engaged in modelling School Education in Bengal. His aim was to find out a model to predict the number of types of schools, which would be needed for a planned development of education with respect to employment. I will recommend this type of study for skill development through education in Schools of India. He left Rajshahi in 1945 after political riots and returned to Calcutta to work in Bengal secretariat. He retained this position until his retirement at the age of 55. After retirement, he served as Registrar of Calcutta University.

Chapter 5 proves that SD was a multi-talented writer. He was supporter of teaching Science in Bengali language. For this purpose, he wrote a popular science book in 1955 for school children under the title "Saral Vigyan". It deals with physics, chemistry and biology subjects. He also wrote Text books of Physics for B.Sc. students. His contribution in the field of Education is praise worthy: "SD and S.C. Sen wrote a report on the progress of education in West Bengal. The authors did a general survey on the prevailing conditions, and made suggestion about the structure of education on the 'Primary-', 'Middle-', 'High-' School and University level. The report also dealt with 'Adult Education' and 'Vocational and Technical Education'"

The author has tried to evaluate impact of Datta's work in Chapter 6. An analysis of his research contributions has been made to highlight the impact of his work at national and international levels. In Chapter 7, author tries to justify the contributions of S. Datta calling him founder of absorption spectroscopy in India. In the estimation of Rajinder Singh: "SD was a multi-talented person, who tried to popularize science in Bengali. However, he did not get credit for it. He did not have successful students to keep his legacy alive. He did not establish 'a school' or an institute; we have seen his involvement in education committees, and definitely he influenced the future school education system in India".

The last 22 pages of this volume are dedicated to miscellaneous topics relevant to the theme under discussion. List of Publications collected from INSA and Proceedings of ISCA (Indian Science Congress Association) are listed separately. It is followed by an exhaustive Bibliography which is a special feature of author's books. I may point out minor typos in the

text, for example, quality in place of quantity (Section 3, page 44), salvia in place of saliva (Section 1, page 79).

Overall, this volume is a welcome addition to history of science in India. It needs to be mentioned that Rajinder Singh has already published monographs on unsung heroes of Indian Science, namely, Upendra Nath Brahmachari, Bidhu B. Ray, Sisir K. Mitra, Sukumar C. Sirkar, Debendra M Bose, and Kedareshwar Banerjee. The present volume is a continuation of the same tradition set up by the author.